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Abbreviations 
 
7-DHC   7-dehydrocholesterol 
ABC   ATP-binding cassette transporters  
AP   alkaline phosphatase 
APC   antigen presenting cell 
APM   antigen-presenting molecule 
APS   ammoniumpersulfate 
ATP   adenosine triphosphate 
BrHPP   bromohydrine pyrophosphate 
BSA   bovine serum albumin 
CA   calyculin A 
CCR7   CC-chemokine receptor 7 
CFTR    cystic fibrosis transmembrane conductance regulator  
cDNA   complemantary deoxyribonucleic acid 
CDR   complementarity determining region 
cpm   counts per minute 
DC   dendritic cells 
DETC   dendritic epithelial T cells 
DIDS   4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid  
DMAPP  dimethylallylpyrophosphate 
DMSO   dimethylsulfoxide 
DN   double negative 
DP   double positive 
EDTA    ethylenediamine-tetraacetic acid 
ELISA   Enzyme Linked Immunosorbent Assay 
FACS   fluorescence activated cell sorting 
FCS   fetal calf serum 
FPP   farnesylpyrophosphate 
GGPP   geranylgeranylpyrophosphate  
GM-CSF  granulocyte-macrophage colony-stimulating-factor 
cGMP   cyclic guanosine monophosphate 
GPP   geranylpyrophosphate 
h   hour(s) 
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HLA   human leukocyte antigen 
HMB-PP  (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate 
HMGR   3-hydroxymethyl-3-glutaryl-CoenzymeA-reductase 
HPLC   high performance liquid chromatography 
HRP   horse radish peroxidase 
HS   human serum 
HSA   human serum albumin 
IELs   intraepithelial lymphocytes 
IFNγ   interferon gamma 
Ig   immunoglobulin 
IL   interleukin  
IPP   isopentenylpyrophosphate 
i.t.   intra thymic 
kDa   kilo Dalton 
KGF   keratinocyte growth factor 
LC-ESI-MS   liquid chromatography-electrospray-mass spectrometry  
mAb   monoclonal antibody 
MCT   monocarboxylate transporters 
MEP   2-C-methyl-D-erythritol 4-phosphate 
MEV   mevastatin 
MHC   major histocompatibility complex 
min   minute(s) 
MOI   multiplicity of infection 
Mon   monensin 
MDR    multi-drug resistance protein 
MRP    multi-drug related protein  
MVD   diphosphomevalonate decarboxylase 
MVK   mevalonate kinase 
MVL   mevalonolacton 
nBP   nitrogen-containing bisphosphonate drugs 
NK   natural killer 
ND   not determined 
OA   okadaic acid 
OATP   organic anion-transpoting polypeptide  
Abbrevations 
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PAM   pamidronate 
PBMC   peripheral blood mononuclear cells  
PBS   phosphate buffered saline solution 
PCR   polymerase chain reaction 
PHA   phytohemagglutinin 
PMSF   phenylmethylsulfonylfluoride 
PMVK   phosphomevalonate kinase 
Rag   recombination activating gene 
SBA   sec-butylamine 
SCID   severe combined immunodeficiency  
SDS   sodiumdodecylsulfate 
shRNA   small hairpin RNA 
SLC   secondary lymphoid-tissue chemokine 
SP   single positive 
SUR   sulfonylurea receptors 
TAP   trasporter associated with antigen processing 
TCR   T cell receptor 
TE   Tris-EDTA buffer 
TEC   thymic epithelial cells 
TEA   triethylammonium-acetate 
TEMED  N,N,N',N'-tetramethylethylenediamine 
Tg   transgenic 
TNFα   tumor necrosis factor alpha 
U   unit(s) 
Wt   wild type 
ZOL   zoledronate 
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Summary 
 
 T cells are divided into two populations according to the type of TCR used 
for antigen recognition. One population uses a TCR heterodimer, which is 
composed by the non-covalently associated alpha and beta chains. This TCR 
recognizes protein and lipid antigens, which are presented by MHC and CD1 
antigen-presenting molecules, respectively. A second population uses a TCR 
heterodimer composed by the gamma and delta chains and recognizes non-
peptidic ligands in the absence of MHC and CD1 restriction. In humans the major 
population of TCR γδ cells uses the Vγ9-Vδ2 TCR. This is a unique population 
because it is present only in primates and constitutes >50% of peripheral TCR γδ 
cells. TCR Vγ9-Vδ2 cells are activated by microbial phosphorylated metabolites 
and by so far unknown ligands expressed by a group of tumor cells. The principal 
microbial antigen is (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), 
an intermediate metabolite generated in 2-C-methyl-D-erythritol 4-phosphate 
(MEP) pathway of isoprenoids biosynthesis.  
Despite these cells were described in 1986, many aspects remain unclear, 
including the nature of the stimulatory ligands present in tumor cells, the 
mechanisms of their activation during infection, the molecular mechanisms 
involved in antigen presentation, and the requirements for thymic maturation. In 
this dissertation we have addressed these important issues using ex vivo cells, 
biochemical approaches for ligand identification, T cell activation assays and 
generation of transgenic mice expressing this human TCR.  
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We have identified endogenous metabolites generated in the mevalonate 
pathway as the tumor ligands which stimulate TCR Vγ9-Vδ2 lymphocytes. We 
have found that tumor cells show altered mevalonate pathway which leads to 
accumulation of intermediate metabolites. This is novel mechanism utilized by 
the immune system to monitor the metabolic integrity of cells and to react to 
those which have a dysregulation of this important metabolic pathway. 
In a second series of studies we have investigated how TCR Vγ9-Vδ2 cells 
are activated during bacterial infections. Despite published studies identified 
HMB-PP as a potent stimulatory ligand in vitro, there was no formal evidence that 
this compound participates in cell activation during infection. Unexpectedly, we 
found that HMB-PP is not the major stimulatory ligand during infection and 
instead endogenous mevalonate metabolites are the stimulatory ligands. We 
describe how infection modifies the 3-hydroxy-3-methyl-glutaryl-CoA reductase 
(HMGR), which is the key enzyme of the mevalonate pathway, and promotes 
increased synthesis of stimulatory metabolites. We show that infection induces a 
transient increase in HMGR protein levels and dephosphorylation, leading to 
increased enzymatic activity. This alteration occurs already within 1 hour after 
infection, thus representing a rapid mechanism reacting to infection. Thus, like 
with recognition of tumor cells, also during infection, the immune system of 
primates utilizes a mechanism which detects alterations of an important 
metabolic pathway. 
 We also investigated the mechanisms how mevalonate metabolites traffic 
within cells. We found that these ligands, which are generated within the 
Summary 
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cytoplasm, are transported to the cell surface, where they interact with the TCR 
γδ, by the MRP5 transporter. We showed that MRP5-blocking drugs inhibit 
presentation to TCR γδ cells that over expression and knocking down of MRP5 
protein increase and inhibit ligand presentation, respectively. These results show 
that like peptides, which are transported from cytoplasm to the ER through the 
ABC transporters TAP1 and TAP2, also TCR γδ ligands utilize ABC transporters 
to become immunogenic. We also found that MRP5 is not involved in forming 
complexes presented to the TCR γδ and that other unknown ubiquitous and non-
polymorphic molecules are involved in this process. 
 In the last part of these studies we investigated the requirements for 
thymic maturation and peripheral expansion of TCR Vγ9-Vδ2 cells. We generated 
a transgenic (Tg) mouse model in which T cells express a TCR composed by 
human Vγ9-Vδ2 chains. Tg thymocytes express molecules characteristic of 
partially mature thymocytes together with high levels of Tg TCR. Tg cells do not 
acquire a mature phenotype and do not exit the thymus in the absence of TCR 
triggering. However, upon injection of TCR-specific mAbs, Tg thymocytes 
undergo maturation and colonize peripheral lymphoid organs. Mature Tg T cells 
remain in the periphery for up to 6 months, with a phenotype of naïve T cells and 
strongly react to physiological ligands when stimulated by human antigen-
presenting cells, which express the restriction element. Thus, Tg T cells 
expressing the human TCR Vγ9-Vδ2 resemble TCR αβ cells since they also 
require selection events during thymic maturation.  
Summary 
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 Our studies suggest that TCR Vγ9-Vδ2 cells by reacting to cells 
which accumulate mevalonate metabolites provide an early immune response 
during the time when antigen-specific TCR αβ cells have not yet been recruited 
and expanded. Thus, TCR γδ cells fulfill the role of sentinel cells which monitor 
the metabolic integrity of other cells. These cells undergo thymic selection events 
and require the presence of unique molecules for efficient antigen presentation. 
Our studies indicate novel aspects of some of these important processes. 
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Introduction 
 
TCR γδ cells represent a lymphocyte population phenotypically and 
functionally diverse from TCR αβ cells. They have been found in all vertebrates 
examined so far including humans (Brenner et al., 1986), monkeys (Malkovsky et 
al., 1992), mice (Saito et al., 1984; Raulet et al., 1991), rats (Lawetzky et al., 
1990), rabbits (Isono et al., 1995), sheep (Hein and Mackay, 1991), cattle 
(Mackay and Hein, 1989), horses (Schrenzel and Ferrick, 1995), pigs (Hirt et al., 
1990; Saalmuller et al., 1990) and chicken (Bucy et al., 1988; Sowder et al., 
1988). 
They usually represent a small proportion (1-10%) of circulating 
lymphocytes in most adult animals, while they represent a major proportion in 
certain extra-lymphoid sites. TCR γδ cells differ from classical MHC restricted T 
cells in terms of TCR diversity, requirements for antigen recognition and their role 
in immunity and tissue homoeostasis.  
 
Genetic organization of TCR γ and δ loci 
TCR γ and TCR δ chains genes, like TCR α, TCR β and immunoglobulins 
chain genes, are assembled during somatic rearrangement processes.  
In human the TCR γ locus maps on chromosome 7 (Murre et al., 1985) and is 
composed of two constant gene segments (Cγ), five joining elements (Jγ) and 
fourteen variable (Vγ) genes of which six encode functional proteins and eight are 
pseudogenes (Lefranc and Rabbitts, 1990), (Figure 1A). These six genes can be 
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subdivided into two families: the VγI family composed of Vγ2, 3, 4, 5 and 8 genes 
and VγII consisting of Vγ9 (Vγ2 in other nomenclature) gene. The TCR γ chain 
undergoes Vγ-Jγ rearrangement and its variability at junctions is crated by 
addition of not germline encoded nucleotides (N nucleotides) during 
recombination process by terminal deoxynucleotidyl transferase (Tdt), (Strauss et 
al., 1987; Huck et al., 1988).  
 
Vα Vα Vα VδVα/δ VδDδ1-3 Jδ1-4 Cδ CαJαn
Vγ Jγ1 Jγ2Cγ1 Cγ2
A
B
 
 
Figure 1. Genetic organization of human (A) TCR γ locus and (B) TCR δ locus adapted 
from (Hayday, 2000). TCR V segments are green and pseudogens are grey; C 
segments are red; J segments are blue and D segments are yellow. Only some Vγ and 
Vα are indicated. 
 
TCR δ locus is closely linked to TCR α locus in contemporary mammals 
(Hayday et al., 1985; Hayday, 2000). In humans the δ locus is located within the 
TCR α locus on chromosome 14 (Collins et al., 1985), between Jα and Vα gene 
segments (Griesser et al., 1988), (Figure 1B). TCR δ chain is assembled via V-D-
J rearrangement. The TCR δ locus is composed of single Cδ gene segment, four 
different Jδ segments preceded by three diversity (Dδ) elements (Chien et al., 
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1987; Hata et al., 1987; Takihara et al., 1989). Some of V segments are used 
both as Vδ and Vα (Guglielmi et al., 1988; Takihara et al., 1989). Although eight 
distinct Vδ genes have been localized, only six of them were found expressed on 
the cell surface (Arden et al., 1995; Migone et al., 1995). The variability of TCR δ 
chain can be extremely high due to the Dδ segments that can undergo tandem 
rearrangement (Boehm et al., 1988) and flexible reading frame usage (Hata et 
al., 1988) creating diverse length and composition of the joining regions.  
Therefore, despite the limited number of germline encoded elements for the TCR 
γδ, the potential repertoire of this TCR is at least three orders of magnitude 
higher than TCR αβ repertoire due to the extremely high variability in the CDR3 
regions (Davis and Bjorkman, 1988; Hata et al., 1988). Comparison of the CDR3 
length reveled that TCR γδ is more similar to immunoglobulins than to TCR αβ 
(Rock et al., 1994). 
 
Assembly of TCR γδ chains 
The particular feature of TCR γδ is the preferential association of Vδ 
chains with certain Vγ chains. In humans Vδ2 chain is usually associated with 
unique Vγ chain: Vγ9-JP-Cγ1 while Vδ1 and Vδ3 chains are mostly paired with 
various Vγ elements from VγI gene family using Cγ2 (Sturm et al., 1989; Hayday, 
2000). Cγ1 gene segment usage allows formation of disulphate bond between 
TCR chains while usage of Cγ2 results in non-disulphate linkage (Krangel et al., 
1987; Littman et al., 1987). 
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TCR γδ structure 
 Crystal structure of human TCR Vγ9-Vδ2 revealed distinct differences as 
compared to TCR αβ or to antibody Fab fragments. TCR γδ has an unusual 
shape due to the small elbow angle and a small Vγ-Cγ inter-domain angle. The 
elbow angle, between pseudo two-fold symmetry axes that relate V to V and C to 
C (Lesk and Chothia, 1988), of TCR γδ is 110° while Fabs and TCR αβ have 
elbow angles in the range of 125-225° and 140-159°, respectively (Allison et al., 
2001), (Figure 2). 
 
 
 
Figure 2. TCR γδ  and TCR αβ structures aligned to the V domains. 
The C domains of TCR γδ are yellow while V domains are red. In the TCR αβ blue are 
the C domains and green are V domains. Black lines indicate pseudo two-fold symmetry 
axes. The values for elbow angles are indicated. PDB accession numbers for TCR γδ 
and TCR αβ are 1hxm and 1qsf, respectively. 
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The inter-domain angles, between the long axis of the C domains and long 
axis of the V domains, of TCR γδ have 42° for Cγ-Vγ and 101° for Cδ-Vδ. In 
contrast antibodies and TCR αβ have average inter-domain angles of 92° (VL-CL, 
σ=9°), 76° (VH-CH, σ=11°), 100° (Cα-Vα, σ=4°) and 67° (Cβ-Vβ, σ=3°). 
Therefore, the 42° of Cγ-Vγ is the smallest inter-domain angle among these 
receptors. Moreover TCR γδ differ from TCR αβ also in the structure of C 
domains. The FG loop of Cγ is much smaller that the one of Cβ suggesting 
different binding with CD3ε subunit. The secondary structure of Cδ is composed 
of a regular immunoglobulin-like domain with three-stranded β-sheet as its outer 
face and therefore differs from the one or Cα (Allison et al., 2001) 
The structural difference between TCR αβ and TCR γδ most likely reflects 
that these receptors recognize structurally different molecules. 
 
TCR γδ-CD3 complex 
The main difference between TCR αβ- and TCR γδ-CD3 complexes is 
their requirement for CD3δ chain. TCR γδ-CD3 complex, unlike TCR αβ, does not 
associate with CD3δ and contains only CD3γε dimers (Dave et al., 1997; Hayes 
and Love, 2002). The lack of CD3δ chains, unlikely for TCR αβ (Delgado et al., 
2000), does not affect the ERK activation occurring upon TCR stimulation (Hayes 
and Love, 2002).  
The difference in the recruitment of signaling molecules provides a 
difference in signaling potential of these T cell receptors. In fact TCR γδ cells, 
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upon CD3ε stimulation, have better proliferative response than TCR αβ cells 
(Hayes and Love, 2002). Therefore enhanced signaling capacity of TCR γδ cells 
together with their localization and recognition of native antigens allows these 
cells to respond rapidly and acquire effector functions faster than TCR αβ cells 
(Hiromatsu et al., 1992; Ferrick et al., 1995; Hayday, 2000; Hayes and Love, 
2002). 
 
Development of TCR γδ cells 
 TCR αβ and γδ cells develop in the thymus from the pluripotent CD34+ 
precursor cells deriving from bone marrow but distinct from stem cells (Res et al., 
1996). In humans immature thymocytes can be divided accordingly to the 
expression of CD34, CD38 and CD1a (Spits et al., 1998; Spits, 2002). The 
earliest thymic progenitors are CD34+CD38-CD1a-, followed by 
CD34+CD38+CD1a- and CD34+CD38+CD1a+ cells, with CD1a expression 
correlating with T linage commitment (Sanchez et al., 1994). In the next stage 
cells start to express CD4, but not CD8, and they are referred to as CD4+ 
immature single positive (CD4 ISP) cells (Kraft et al., 1993; Spits, 2002). 
Importantly, this population contains precursors for both TCR αβ and γδ cells 
meaning that these cells are before β-selection checkpoint (Ramiro et al., 1996; 
Blom et al., 1999). The CD4 ISP stage is followed by cells that express CD4 and 
CD8α chain, and referred to as early double positive (EDP) cells (Spits, 2002). 
Recently it has been shown that within the population of EDP there are still 
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present cells uncommitted to the linage. The TCR γδ developmental potential is 
only lost on double positive (DP) stage (Joachims et al., 2006).  
Up to date there are no clear evidences that TCR γδ cells are undergoing 
selection process in the thymus. However, the TCR γδ repertoire generated in the 
human thymus is much more diverse than the one present in the periphery where 
TCR Vγ9 chain pairs only with TCR Vδ2 chain (Casorati et al., 1989; Krangel et 
al., 1990), thus suggesting that certain selection of TCR γδ cells takes place in 
the thymus. 
More extensive studies concerning TCR γδ cells development have been 
performed using mouse models. In mice TCR γδ cells and TCR αβ cells also 
develop from a common thymic double negative (DN) precursor but they diverge 
into separate lineages very early in ontogeny (Petrie et al., 1992; Dudley et al., 
1995). 
Immature αβ lineage cells expressing pre-TCR undergo proliferation and 
transition to CD4 CD8 DP stage (Fehling et al., 1995). DP thymocytes which 
express mature TCR αβ, follow positive and/or negative selection and emerge as 
CD4 or CD8 single positive (SP) thymocytes (Fehling et al., 1995 ). In contrast γδ 
lineage cells during differentiation do express mature TCR γδ complex, remain 
mainly DN and undergo limited proliferation (Pardoll et al., 1988).  
The developmental stage at which γδ lineage diverges from αβ lineage 
presumably occurs between the CD44+CD25+ (DN2) and CD44-CD25- (DN4) 
stage (Shortman et al., 1991; Petrie et al., 1992; Kang et al., 2001). There are 
indications that TCR γδ-dependent developmental checkpoint take place already 
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at DN3 stage (Prinz et al., 2006; Taghon et al., 2006), (Figure 3). Progression 
through this checkpoint is marked by high expression of CD27 on TCR γδ cells 
(Taghon et al., 2006). 
 
DN1 DN2 DN3a
DN3b
DN3b
γδ
DN4 DP
CD4+
CD8+
TCRγ, TCRδ, TCRβ
rearrangements
TCRα rearrangement
γδ-s
ele
ctio
n
β
-selection
TCR αβ-positive
selection
 
 
Figure 3. Schematics of thymic T cell development of TCR αβ and TCR γδ cells modified 
from (Hayday and Pennington, 2007). 
 
TCR γ and δ gene rearrangements are initiated at DN2 stage whereas 
rearrangement of TCR β gene is slightly delayed and begins between DN2 and 
DN3 stages (Livak et al., 1999).  
The αβ/γδ lineage choice is mediated by single TCR and regulated by the 
strength of TCR signal (Hayes et al., 2003; Haks et al., 2005; Hayes et al., 2005) 
and by Notch signaling (Garbe and von Boehmer, 2007). Strong TCR signals 
through TCR γδ or TCR αβ direct either the development of DN γδ lineage cells 
or MHC independent development of TCR αβ cells with γδ DN phenotype 
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(Terrence et al., 2000; Garbe and von Boehmer, 2007), (Figure 4A). Instead 
weak TCR signals (from pre-TCR or TCR γδ or TCR αβ) in synergy with Notch 
signaling would favor the αβ lineage commitment (Figure 4B), (Garbe and von 
Boehmer, 2007). 
 
TCR γδ TCR γδ
TCR αβ TCR αβ
DN
strong TCR signaling weak TCR signaling and Notch signaling
pre-TCR TCR αβ
DP
TCR γδ
TCR αβ
A B
DN
 
 
Figure 4. Influence of TCR signal strength and Notch signaling on the αβ/γδ lineage 
choice adapted from (Garbe and von Boehmer, 2007). 
(A) Strong signaling by the TCR γδ or the TCR αβ results in differentiation into DN 
γδ lineage cells or DN cells with a γδ lineage phenotype but TCR αβ expression. 
(B) Weak signal by the TCR γδ, pre-TCR or TCR αβ together with Notch signaling results 
in differentiation into αβ lineage cells. 
 
Recently involvement of Sox13 transcription factor in regulation of αβ/γδ lineage 
differentiation has been shown. Sox13 is essential for the proper development of 
TCR γδ cells, but not TCR αβ cells. It is highly expressed on DN1 and DN2 cells 
and subsequently downregulated in αβ-lineage differentiating cells. Significant 
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levels of Sox13 are maintained in peripheral TCR γδ cells. Since Sox 13 
expression by DN2 cells is heterogenous (50% of DN cells are positive for 
Sox13) it has been suggested that some lineage separation occurs even before 
TCR rearrangement (Melichar et al., 2007). 
 TCR γδ cells developing in adult, but not fetal thymus, require a significant 
number of DP thymocytes which trans regulate differentiation of TCR γδ cells 
through involvement of transcription factor RORγt and lymphotoxin β receptor 
(LTβR). The proper signaling from LTβR is essential for correct TCR γδ biased 
gene expression which is required for the proper function of TCR γδ cells. Thus 
the trans conditioning overall influences rather cell’s functional competences than 
commitment to the lineage (Pennington et al., 2003; Silva-Santos et al., 2005; 
Hayday and Pennington, 2007). 
Another factor important for the proper development of TCR γδ cells is IL-7 
receptor signaling which promotes the expansion and survival of TCR γδ cells in 
the thymus. Moreover, it is also required for the proper recombination of TCR γ 
locus (Ikuta et al., 2001). 
An important question which remains to be answered is whether TCR γδ 
requires ligand engagement for the proper TCR γδ cells development. Up to date 
only indirect evidence suggest the requirement for ligand-mediated positive 
selection in fetal thymus of the dendritic epidermal T cells (DETC), (Xiong et al., 
2004; Lewis et al., 2006). This subset of TCR γδ cells populates mouse skin. 
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TCR γδ cell tissue distribution 
 TCR γδ cells comprise 1-5% of circulating T cells while they are very 
abundant in tissues. In human TCR γδ cells expressing TCR Vδ1 or Vδ3 chains 
are predominant in the epithelium of the intestine (De Libero et al., 1993) where 
they comprise the majority of intraepithelial lymphocytes (IELs). Cells bearing 
TCR Vδ2 chain localize mainly in secondary lymphoid organs, tonsils and 
peripheral blood where they represent 5-10% of total lymphocytes (Casorati and 
Migone, 1990; Parker et al., 1990; Haas et al., 1993). Importantly, in humans and 
some primates about 50-80% of all TCR γδ express restricted TCR composed by 
the Vγ9 and Vδ2 chains (Porcelli et al., 1991). In the postnatal thymus TCR Vγ9-
Vδ2 cells constitute a minor population (up to 1% of total thymocytes), (Casorati 
et al., 1989; Falini et al., 1989) but they expand in the periphery, probably due to 
the continuous stimulation by unknown factors (Parker et al., 1990).  
Also in mice certain populations of TCR γδ cells localize in epithelia of 
particular organs. In the epidermis DETC account for ~100% of resident IELs. 
They have TCR composed of Vγ3 and Vδ1 chains lacking junctional diversity 
(Havran and Allison, 1990). TCR Vγ4 chain is predominantly expressed in the 
reproductive tract, lung and tongue (Itohara et al., 1990). In the small intestine 
TCR γδ cells preferentially use Vγ5 and Vγ1.1 chains (Pereira et al., 2000) while 
in the secondary lymphoid organs TCR γδ cells mainly express Vγ2, Vγ1.1 and 
Vγ1.2 chains (Raulet et al., 1991; Pereira et al., 2000). 
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The tissue specific distribution of cells expressing particular TCR γδ 
heterodimers most likely is associated with recognition of ligands present at the 
localization site. 
 
TCR γδ stimulatory antigens 
Natural non-peptidic phosphorylated antigens 
 The main population of human TCR γδ cells expressing TCR Vγ9-Vδ2 
respond in vitro to pathogen derived (both bacterial and parasite) extracts (Morita 
et al., 2000). The stimulatory components, obtained form mycobacteria cell 
lysates, have small molecular weight (less than 500 Da), are protease-resistant 
and contain critical phosphate residue (Pfeffer et al., 1990; Constant et al., 1994; 
Schoel et al., 1994; Tanaka et al., 1994). The analysis of Mycobacterium 
smegmatis culture supernatants resulted in identification of 
isopentenylpyrophosphate (IPP) and its hydroxymethyl derivatives as natural 
TCR γδ ligands (Tanaka et al., 1995). These compounds are intermediate 
metabolites of isoprenoids biosynthesis. In eukaryotes, archaebacteria and 
certain eubacteria the biosynthesis of IPP proceeds via mevalonate pathway, 
while in many eubacteria and plastids of algae and higher plants, IPP is supplied 
by 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway (Eberl et al., 2003), 
(Figure 5 and Table 1). 
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Figure 5. Schematics of prokaryotic MEP and eukaryotic mevalonate pathways of 
isoprenoids biosynthesis. 
(A) MEP pathway with indicated genes coding enzymes. 
(B) Mevalonate pathway with indicated selected enzymes. 
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Organism MEP pathway Mevalonate pathway 
Prokaryotes 
  
Eubacteria   
Mycobacterium tuberculosis + - 
Mycobacterium leprae + - 
Escherichia coli + - 
Haemophilus influenzae + - 
Chlamydia pneumoniae + - 
Pseudomonas aeruginosa + + 
Listeria monocytogenes + + 
Staphylococcus aureus - + 
Streptococcus pneumoniae - + 
Borrelia burgdorferi - + 
Archaebacteria   
Pyrococcus horikowskii - + 
Methanobacterium - + 
Eukaryotes   
Apicomplexan parasites   
Plasmodium farciparum + - 
Plants   
Arabidopsis thaliana + + 
Fungi   
Saccharomyces ceravisiae - + 
Mammals - + 
 
Table 1. Utilization of MEP and mevalonate pathways by selected organisms, adapted 
from (Morita et al., 2000). 
 
Beside IPP also other mevalonate pathway metabolites, including 
dimethylallylpyrophosphate (DMAPP), farnesylpyrophosphate (FPP), 
geranylgeranylpyrophosphate (GGPP) and geranylpyrophosphate (GPP), (Burk 
et al., 1995; Tanaka et al., 1995; Morita et al., 1999), (Figure 6) behave as TCR 
Vγ9-Vδ2 cells ligands, although with a potency 30-300 times lower than that IPP. 
Furthermore, an antigenic intermediate of bacterial MEP pathway, (E)-4-hydroxy-
3-methyl-but-2-enyl pyrophosphate (HMB-PP) was identified as very strong TCR 
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γδ antigen (Hintz et al., 2001), (Figure 6). The reactivity of human peripheral 
blood mononuclear cells (PBMC) towards HMB-PP is restricted to TCR Vγ9-Vδ2 
cells and leads to upregulation of activation markers, secretion of pro-
inflammatory cytokines and expansion of these TCR γδ cells (Hintz et al., 2001; 
Eberl et al., 2002; Reichenberg et al., 2003). 
The stimulatory capacity of HMB-PP for TCR Vγ9-Vδ2 cells is 
approximately four orders of magnitude higher than IPP. Therefore it was 
suggested that HMB-PP is the key activator of TCR Vγ9-Vδ2 cells during 
bacterial infection (Eberl et al., 2003). This aspect will be further discussed in this 
work. 
 
 
 
Figure 6. Structures of selected natural prenyl pyrophosphates. 
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Synthetic stimulatory ligands for TCR Vγ9-Vδ2 cells 
Up to date a number of synthetic compounds (Figure 7) that are able to 
stimulate TCR Vγ9-Vδ2 cells have been synthesized, including methyl 
phosphate, monoethyl pyrophosphate (Tanaka et al., 1994), bromhydrin 
pyrophosphate (BrHPP, PhosphstimTM), (Belmant et al., 2000; Espinosa et al., 
2001) and 2-methyl-3-butenyl-1-pyrophosphate (2M3B1PP), (Tanaka et al., 
2007). These compounds specifically activate TCR Vγ9-Vδ2 cells which upon 
stimulation release cytokines and induce target cell lysis (Belmant et al., 2000). 
As compared with naturally occurring ligands synthetic compounds are very 
strong agonist i.e. BrHPP have half-maximal activity in the nano molar 
concentration range (Belmant et al., 2000; Espinosa et al., 2001). Currently 
BrHPP and 2M3B1PP are produced in large scale amounts and are being used 
for clinical trials. 
 
 
 
Figure 7. Structures of selected stimulatory synthetic phosphorylated antigens. 
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Another group of synthetic compounds are nitrogen-containing 
bisphosphonates (nBP). There drugs prevent bone resorption and are used for 
treatment of Paget’s disease (Hosking, 2006), tumor-associated bone diseases 
(Sauty et al., 1996; Berenson et al., 2001; Tripathy et al., 2004) and osteoporosis 
(Boonen et al., 2005). They induce selective expansion of TCR Vγ9-Vδ2 cells in 
peripheral blood of human beings after intravenous administration (Kunzmann et 
al., 2000). Activated by nBP TCR γδ cells secrete pro-inflammatory cytokines and 
kill target tumor cells in vitro (Kunzmann et al., 2000). Structural similarities of 
nBP and bacterial antigens suggested that they might mimic natural ligands 
(Kunzmann et al., 1999), (Figure 8). 
 
 
 
Figure 8. Structures of selected biological active nBP. 
 
Importantly, nBP by blocking farneslypyrophosphate-synthase (FPP-
synthase), (Thompson et al., 2002) one of the enzymes in the mevalonate 
pathway (Figure 5), lead to accumulation of IPP/DMAPP in vitro (Bergstrom et 
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al., 2000). Therefore, nBP could increase levels of intracellular ligands 
responsible for activation of TCR γδ cells (see this work). 
 
Alkylamines  
Different class of compounds activating TCR Vγ9-Vδ2 cells in an antigen 
specific manner are alkylamines (Bukowski et al., 1999). These small organic 
molecules contain short (two to five carbon atoms) alkyl chain linked to positively 
charged amine group (Figure 9). Alkylamines are produced and secreted by 
several bacterial strains (Daneshvar et al., 1989; Bukowski et al., 1999). They 
were also found in plants (apples), (Hartmann, 1967) and plant products (tea or 
wine), (Asatoor, 1966; Ibe et al., 1991). In order to stimulate TCR γδ cells, 
alkylamines must be present in milli molar concentrations which are unlikely 
present in vivo. This raises the question of the physiological relevance of 
alkylamines of TCR γδ activation and of the mechanisms how they are active.  
 
 
 
Figure 9. Structures of selected alkylamines. 
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TCR Vγ9-Vδ2 antigen recognition 
TCR Vγ9-Vδ2 cells are activated in a crossreactive manner by variety of 
ligands like IPP, DMAPP, 2,3-diphosphogyceric acid (DPG), glycerol-3-
phosphate (G3P), xylose-1-phosphate (Xyl-1P) , ribose-1-phosphate (Rib-1-P), 
(Burk et al., 1995). Optimal stimulation of TCR γδ cell is driven by cells of human 
origin (De Libero et al., 1991). The recognition of phosphate-containing antigens 
requires cell-cell interactions without the need for antigen processing (De Libero 
et al., 1991; Kabelitz et al., 1991; Lang et al., 1995; Morita et al., 1995). Taken 
together this suggests the existence of a dedicated antigen-presenting molecule. 
TCR Vγ9-Vδ2 cells recognize phosphorylated antigens in the absence of MHC or 
CD1 restriction since APC lacking MHC class I, β2-microglobulin, CD1, or MHC 
class II molecules are able to activate TCR Vγ9-Vδ2 cells (Morita et al., 1995). 
Moreover, tumor cell lines and normal PBMCs are able to activate TCR Vγ9-Vδ2 
cells form different donors (Morita et al., 1995). Thus, the putative antigen-
presenting molecule has rather limited or no polymorphism and is constitutively 
expressed in a variety of tissues. 
 
TCR γδ cells reactivity to MHC and MHC–like molecules 
CD1c restricted TCR γδ cells 
Human TCR γδ composed of Vδ1 chain paired with either Vγ1 or Vγ2 
chains recognize CD1c molecule which is mainly expressed on immature DC and 
B cells (Faure et al., 1990; Spada et al., 2000). CD1c is a member of CD1 family 
molecules which are non-MHC-encoded proteins sharing structural similarities 
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with MHC class I molecules. CD1 antigen-presenting molecules have little 
polymorphism and are specialized in the presentation of lipids and glycolipids 
(Beckman et al., 1994; Matsuda and Kronenberg, 2001; De Libero and Mori, 
2003).  
This recognition occurs in the absence of exogenous foreign antigen 
(Spada et al., 2000; Vincent et al., 2002) suggesting reactivity against self-lipid 
loaded into CD1c molecule (De Libero and Mori, 2003). TCR γδ cells upon 
recognition of CD1c secrete pro-inflammatory cytokines which contribute to the 
DC maturation process (Ismaili et al., 2002; Leslie et al., 2002). In addition, they 
have a cytolytic, Th1 effector phenotype and produce granulysin (Spada et al., 
2000). 
 
MIC and ULBP reactive TCR γδ cells 
 Subset of TCR Vδ1+ cells have been found to interact with cells 
expressing stress-induced MHC class I-related chain (MICA and MICB) 
molecules (Groh et al., 1998) and UL16-binding protein (ULBP family) molecules 
(Poggi et al., 2004). MIC are encoded within the MHC locus (Bahram et al., 
1994) while ULBPs are encoded by genes on chromosome 6q25. MIC proteins 
are upregulated in response to cellular stress like heat shock in intestinal 
epithelium and on epithelial tumors (Groh et al., 1996; Groh et al., 1999) while 
ULBPs are expressed on various cancers of hematopoietic origin including acute 
myeloid and lymphoblastic leukemias (Salih et al., 2003). 
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Despite the structural similarities between MIC and MHC class I 
molecules, MIC do not associate with β2-microglobulin and do not present 
peptides, probably due to the limited size of the putative peptide binding grove 
and conformational differences in α1 and α2 domains (Groh et al., 1998; Li et al., 
1999). TCR Vδ1+ cells interact with MIC trough the TCR (TCR-dependent signal 
1) and through natural killer activating receptor NKG2D (NKG2D dependent 
costimulatory signal 2), (Wu et al., 2002) while ULBPs most likely interact only 
through NK receptors (Cosman et al., 2001).  
 
Other molecules 
Among human TCR γδ cells a few T cell clones, expressing TCR Vδ1 
chain, react to allo–MHC molecules including HLA-A2 (Spits et al., 1990), HLA-
A24 (Ciccone et al., 1989), HLA-B27 (Del Porto et al., 1994) and some 
unspecified class I molecules (Rivas et al., 1989). In al these studies a cognate 
interaction of the TCR γδ with MHC molecules was not formally demonstrated.  
In mouse TCR γδ cells recognizing T10/T22 MHC class Ib molecules 
(Matis et al., 1989; Van Kaer et al., 1991) or I-Ek MHC class II molecule (Matis et 
al., 1989) have been described. Recognition of these molecules is independent 
from the peptide binding and antigen processing (Schild et al., 1994; Crowley et 
al., 2000). In the case of I-Ek recognition depends on the post-translational 
changes in its glycosilation (Hampl et al., 1999). 
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Stimulation by bacterial superantigens 
 Bacterial superantigens are toxins secreted by several bacterial species, 
which activate T cells by binding to the non-polymorphic region of MHC class II 
molecules outside of the antigen binding groove (Kozono et al., 1995) and to the 
Vβ domain of the TCR αβ (Li et al., 1998). TCR Vγ9+ cells are activated by the 
superantigen staphylococcal enterotoxin A (SEA), (Loh et al., 1994; Morita et al., 
2001). This stimulation occurs in a MHC class II dependent but Vδ independent 
manner. TCR γδ cell require higher concentrations of SEA for stimulation as 
compared to TCR αβ cells (Morita et al., 2001). Therefore, due to the structural 
similarity between TCR Vγ and TCR Vβ (Allison et al., 2001) and comparable 
concentrations required for T cell stimulation (Surman et al., 1994) interaction of 
Vγ with SEA might resemble that of Vβ with staphylococcal enterotoxin B. 
 
Effector functions of TCR γδ cells 
Role of TCR γδ cells in microbial infections 
TCR γδ cells were found to expand to high levels during a variety of 
bacterial, viral and protozoan infections. Elevated levels of TCR Vγ9-Vδ2 cells in 
the peripheral blood were observed in patients infected with Mycobacterium 
tuberculosis (Barnes et al., 1992), Mycobacterium leprae (Modlin et al., 1989), 
Listeria monocytogenes (Jouen-Beades et al., 1997), Francisella tularensis 
(Poquet et al., 1998), Brucella melitensis (Bertotto et al., 1993), Salmonella 
typhimurium (Hara et al., 1992), Ehrlichia (Caldwell et al., 1995). Also patients 
with the following parasite infections have increased number of TCR γδ cells: 
Introduction 
 39 
Leishmania donovani (Raziuddin et al., 1992), Toxoplasma ssp (Scalise et al., 
1992), Plasmodium falciparum (Ho et al., 1990). Moreover TCR Vγ9-Vδ2 cells 
may increase in case of Epstein-Barr virus (EBV), (De Paoli et al., 1990) and 
Herpes simplex virus (HSV), (Bukowski et al., 1994) infections.  
 During certain microbial infections TCR Vγ9-Vδ2 cells expand even up to 
50-fold (Table 2). 
 
Infectious disease % of TCR γδ cells Reference 
bacterial 
  
tuberculosis 14 (35) (Balbi et al., 1993) 
tularemia 33 (Sumida et al., 1992; Poquet et al., 1998) 
salmonellosis 18 (48) (Hara et al., 1992) 
brucellosis 29 (48) (Bertotto et al., 1993) 
ehrlichiosis 57 (97) (Caldwell et al., 1995) 
H. influence/meningitis 27 (37) (Raziuddin et al., 1994) 
N. meningititis/meningitis 25 (42) (Raziuddin et al., 1994) 
S. pneumoniae/meningitis 35 (46) (Raziuddin et al., 1994) 
legionellosis 15 (Kroca et al., 2001) 
listeriosis 12 (33) (Jouen-Beades et al., 1997) 
Coxiella brunetii/Q-fever 16 (30) (Schneider et al., 1997) 
parasite 
  
acute malaria (non endemic) 18 (46) (Schwartz et al., 1996) 
toxoplasmosis 9 (15) (Scalise et al., 1992) 
leishmaniases 13 (18) (Russo et al., 1993) 
 
Table 2. Examples of human TCR γδ cells expansion in response to infection. 
Percentage of TCR γδ cells shows mean values detected in patients. Maximal number of 
detected cells is shown in brackets. 
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Expanded and activated TCR Vγ9-Vδ2 cells may directly participate in 
anti-microbial immune responses inducing killing of bacteria, through granulysine 
release, and bacteria-infected cells, through preforin and/or Fas-Fas ligand 
interactions (Hara et al., 1992; Dieli et al., 2000; Ottones et al., 2000). Activated 
TCR Vγ9-Vδ2 cells are able to produce significant amounts of Th1 cytokines: 
IFNγ and TNFα providing an important stimulus for macrophages attraction 
during the early stage of infection (Garcia et al., 1997; Wang et al., 2001). 
Moreover, TCR Vγ9-Vδ2 cells release large quantities of the β-chemokines such 
as macrophage inflammatory protein-1α (MIP-1α, CCL3) and MIP-1β (CCL4), 
(Cipriani et al., 2000). In vitro MIP-1α and MIP-1β attract TCR αβ CD4+ and TCR 
αβ CD8+ cells, respectively (Schall et al., 1993; Taub et al., 1993). Therefore, 
chemokines release by TCR Vγ9-Vδ2 cells might contribute to the pro-
inflammatory microenvironment at the sites of infection. 
The levels of TCR Vδ1/Vδ3 are elevated in renal allograph recipients 
developing cytomegalovirus (CMV) infection (Dechanet et al., 1999a). Moreover 
TCR Vδ2- cells activated by CMV-infected fibroblasts produce large amounts of 
TNFα and kill infected cells. This recognition is mediated by TCR independently 
of MHC class I presentation and without NKG2D engagement (Halary et al., 
2005). Infection with human immunodeficiency virus-1 (HIV-1) leads to 
proliferation of TCR Vδ1 cells in the peripheral blood (Hinz et al., 1994). Most 
likely, these TCR γδ cells are activated in the intestinal epithelia and then migrate 
to the peripheral blood (Dechanet et al., 1999b). 
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In mice TCR γδ cells expand in response to mycobacteria (Janis et al., 
1989), listeria (Hiromatsu et al., 1992) and salmonella (Emoto et al., 1992) 
infections. Importantly, mice lacking TCR γδ cells develop enhanced inflammation 
characterized by disruption of macrophage homeostasis and liver necrosis 
(Carding and Egan, 2002) and they do not survive infections with Listeria 
monocytogenes (Skeen et al., 2001) or Klebsiella pneumoniae (Moore et al., 
2000). Furthermore, in TCR αβ deficient mice, TCR γδ cells provide early 
protective immune responses against listeriosis (Mombaerts et al., 1993) and 
malaria (Tsuji et al., 1994). 
 
Tumor surveillance 
TCR Vγ9-Vδ2 cells have been shown to recognize and kill tumor 
transformed cells like B cell lymphomas (Fisch et al., 1990; Selin et al., 1992), 
thymic lymphomas (De Libero et al., 1991) and erythroleukemia cells (Di Fabrizio 
et al., 1991). Moreover, this population of TCR γδ cells is expanded in blood 
and/or intra-lesions of patients with hemopoietic and solid tumors (Bonneville and 
Fournie, 2005). 
The potent anti-tumor activities of TCR γδ cells have recently stimulated 
great interest in of TCR γδ cells cell-based cancer immunotherapy. TCR Vγ9-Vδ2 
cells expanded ex vivo, with BrHPP and IL-2 and derived from patients with 
metastatic form of renal cell carcinoma have the ability to kill autologus primary 
renal tumor cells (Viey et al., 2005). Furthermore, nBP activated TCR Vγ9-Vδ2 
cells produce cytokines, exhibit specific cytotoxicity against myeloma cell lines, 
Introduction 
 42 
and lead to reduced survival of autologous myeloma cells (Kunzmann et al., 
2000). TCR Vγ9-Vδ2 cells expanded in vitro in the presence of aledronate 
(another nBP) and IL-2 maintain their anti-tumor activity in vivo after adoptive 
transfer into mice with severe combined immunodeficiency (SCID), (Kabelitz et 
al., 2004).  
Promising results in the treatment of patients with low-grade non-Hodgkin 
lymphoma and multiple myeloma were achieved by in vivo stimulation of TCR γδ 
cells using pamidronate and low-dose IL-2. This type of immunotherapy resulted 
in tumor regression (Wilhelm et al., 2003). 
  TCR Vγ9-Vδ2 cells have a phenotype of memory cells (Miyawaki et al., 
1990; De Rosa et al., 2004) and the capacity to promptly release IFNγ and TNFα. 
These characteristics implicate that they can be rapidly recruited to the site of 
tumorgenesis and therefore contribute to early immune protection. 
Human TCR Vδ1 cells exhibit a selective lytic activity against various 
tumor cell lines like colorectal cancer, esophageal cancer, renal cell cancer, 
pancreatic cancer, lung cancer (Ferrarini et al., 1994; Zocchi et al., 1994; 
Choudhary et al., 1995; Maeurer et al., 1996; Groh et al., 1999; Thomas et al., 
2001). The recognition of tumor cells occurs via MIC or ULBP molecules which 
interact directly with NKG2D and possibly with TCR present on TCR Vδ1 cells 
(Groh et al., 1999; Wu et al., 2002; Poggi et al., 2004). Recently, it was reported 
that upon MICA-NKG2D interactions the antigen-dependent effector functions of 
TCR Vγ9-Vδ2 cells can be enhanced (Das et al., 2001a). 
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Tissue homeostasis and repair 
TCR γδ cells from both human and mouse are able to produce 
keratinocyte growth factor (KGF), (Boismenu and Havran, 1994; Workalemahu et 
al., 2003), a cytokine promoting epithelial cell growth (Visco et al., 2004). Human 
TCR γδ cells from bronchoalveolar lavage in the presence of IPP are able to 
secrete fibroblast growth factor 9 (FGF-9), associated with epithelial cell 
proliferation (Workalemahu et al., 2004). 
Furthermore, upon activation with IPP TCR γδ cells secrete metalloproteinase 7 
(MMP7) which serves a key role in epithelium repair (Workalemahu et al., 2006). 
Therefore TCR γδ cells contribute to the maintenance of epithelial homeostasis 
and play a role in the restoring epithelial integrity. 
 Mouse DETCs can be activated in vitro by stressed or damaged 
keratinocytes. Upon activation they secrete KGF which implicates their role in the 
response to skin damage. They also participate in keratinocyte survival by 
constitutively secreting insulin-like growth factor 1 (IGF-1). In addition TCR δ-/- 
mice have problems with tissue repair and keratinocyte homeostasis. The lung 
and intestine TCR γδ cells, exhibit similar roles in the maintenance epithelium 
integrity (Witherden et al., 2000; Jameson and Havran, 2007).  
The fact that TCR γδ cells reside in epithelial tissues of all mammals, 
suggest that they play a conserved role in the monitoring of tissue integrity. 
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TCR γδ cells in autoimmune diseases and inflammations 
There are findings suggesting that TCR γδ cells could be involved in the 
pathogenesis of autoimmune diseases. Accumulation of TCR γδ cells has been 
observed in the inflamed synovium of patients with rheumatoid arthritis 
(Holoshitz, 1999). By using a mouse model of collagen induced arthritis it was 
demonstrated that TCR γδ cells can have pro-inflammatory functions early in the 
disease but anti-inflammatory during the late stage of the disease (Peterman et 
al., 1993). 
The number of TCR Vγ9-Vδ2 cells is increased in the peripheral blood of patients 
with diabetes mellitus (Lang et al., 1991) and in pre-diabetic and diabetic children 
(Gyarmati et al., 1999). The regulatory role of TCR γδ cells in diabetes was 
studied by using non-obese diabetic (NOD) mouse model. The intranasal 
inhalation of pro-insulin leads to the generation of a population of regulatory TCR 
γδ cells that can suppress the development of diabetes (Harrison et al., 1996). 
In case of patients with multiple sclerosis (MS) elevated levels of TCR Vδ1 cells 
were found in the brain lesions (Wucherpfennig et al., 1992) and cerebrospinal 
fluid (Nick et al., 1995). The same population of TCR γδ cells has been found to 
be increased in the blood and intestine of patients with inflammatory bowel 
disease (Soderstrom et al., 1996; McVay et al., 1997).
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Part  1 
 
Intracellular endogenous ligands activating TCR Vγ9-Vδ2 cells  
(These results have been published in The Journal of Experimental Medicine, 
2003, 197, 163-168) 
 
TCR Vγ9-Vδ2 cells recognize bacteria phosphorylated metabolites and 
also react to bone marrow-derived tumor cells such as Daudi Burkitt’s lymphoma 
line (Fisch et al., 1990; Malkovska et al., 1992). In order to identify the nature of 
the tumor antigens we investigated whether TCR γδ cells recognize 
phosphorylated nonpeptidic ligands resembling those produced by microbes. 
One of the potent identified bacterial antigens is IPP, an intermediate product of 
isoprenoids biosynthesis which is present in prokaryotic as well as in eukaryotic 
cells (Burk et al., 1995; Tanaka et al., 1995). Bacteria produce IPP in either MEP 
or mevalonate pathways (Morita et al., 2000), (Figure 5), whereas in eukaryotes 
IPP is generated exclusively in the mevalonate pathway (Figure 5). It was 
previously reported that in some hematological malignancies (Harwood et al., 
1991) and mammary carcinomas (Asslan et al., 1999) expression and function of 
3-hydroxymethyl-3-glutaryl-CoenzymeA-reductase (HMGR), the rate-limiting 
enzyme in the mevalonate pathway, is increased. Based on these findings we 
investigated whether dysregulation of mevalonate pathway in tumors may lead to 
accumulation of mevalonate metabolites thus resulting in activation of TCR Vγ9-
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Vδ2 cells. In the following studies we took advantage of drugs that influence 
enzymes of the mevalonate pathway (Figure 10). 
 
 
 
 
Figure 10. Mevalonate pathway with indicated compounds used in this study and the 
affected enzymes.  
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Results 
 
Active HMGR in tumor cells is required for activation of TCR γδ cells 
Various cell lines of human origin were tested for the capacity to activate 
TCR Vγ9-Vδ2 cells in the presence or absence of exogenous IPP and after 
treatment with ZOL (Table 3).  
 
APC Cell type Medium IPP ZOL 
Daudi Bone marrow, B-cell lymphoma  2527* 14342 5647 
THP-1 Bone marrow, monocytes 197 3135 16393 
CEM 1.3 Bone marrow, T-cell lymphoma 310 6586 1564 
K562 Bone marrow, erythroleukemia 36 2762 1145 
A-375 Skin, melanoma 188 9169 15842 
A-431 Skin, epidermoid carcinoma 89 3269 3067 
Colo 201 Colon epithelia, coloncarcinoma 260 3103 4374 
HEP G2 Liver parenchyma, hepatocarcinoma 96 12040 12417 
HuH6 Liver parenchyma, hepatoblastoma 80 4329 3451 
A-243 Central nervous system, astrocytoma 23 5415 7141 
U118 Central nervous system, glioblastoma 33 2114 5575 
BS 125.3.2 Central nervous system, glioblastoma 46 13942 8440 
MRK-nu-1 Mammary gland, mammary carcinoma 35 3003 1965 
HMC-1-8 Pleural effusion, mammary carcinoma 17 2011 1845 
YMB-1 Mammary gland, mammary carcinoma 1162 3695 1525 
Fibroblasts isolated from primary, lung connective tissue 175 5085 8768 
 
 
Table 3. Tumor cell lines of different tissue origin and primary lung fibroblasts were used 
as APC. Cells were either incubated with medium or IPP (10 µM) or were pulsed with 
ZOL (zoledronate, 50 µg/ml) for 3 h before T cell were added. * Numbers represent 
mean values in pg/ml of TNFα release by the G2B9 TCR γδ clone. 
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We found that not only Daudi cell but also YMB-1 cells, a solid breast carcinoma 
activate TCR γδ cells (Table 3). In order to investigate whether HMGR is involved 
in generation of TCR γδ stimulatory antigens we treated both, Daudi and YMB-1 
cells with mevastatin (MEV), and inhibitor of the HMGR catalytic site (Istvan and 
Deisenhofer, 2001) 2 h before TCR γδ cells addition. Activation of TCR Vγ9-Vδ2 
was strongly reduced in the presence of MEV treated Daudi or YMB-1 cells 
(Figure 11). To rule out toxicity and unspecific inhibitory effect of MEV stimulation 
with exogenous IPP and PHA was also performed (Figure 11).  
 
 
 
Figure 11. TCR γδ cell activation, by tumor cells, depends on active HMGR. 
Daudi or YMB-1 cells, in the absence or presence of MEV, were used as APC in TCR γδ 
cell activation assay. In control experiment stimulation with exogenously added IPP or 
PHA was performed. 
 
HMGR is one of the most tightly regulated enzyme in the cells (Goldstein 
and Brown, 1990). The activity of HMGR is controlled through protein synthesis, 
degradation and phosphorylation (Cheng et al., 1999). In order to further 
investigate the involvement of HMGR in the generation of TCR γδ stimulatory 
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ligands we treated Daudi cells with 7-DHC or farnesol, two endogenous 
metabolites that facilitate degradation of HMGR (Correll et al., 1994; Honda et 
al., 1998). Both compounds induced reduction of intracellular HMGR protein 
levels (Figure 12A) and significantly inhibited TCR γδ activation by Daudi cells 
(Figure 12B). In control experiments TCR γδ cell activation was not inhibited 
when stimulated with exogenous IPP in the presence of these compounds 
(Figure 12B). 
 
 
 
Figure 12. TCR γδ cell activation by tumor cells depends on the HMGR protein level. 
(A) HMGR protein levels in lysates after treatment of Daudi cells with 7-DHC or farnesol 
detected by immunoprecipitation and Western blot. 
(B) Daudi cells treated either with 7-DHC or farnesol were used to stimulate TCR γδ 
cells. As control, activation in the presence of exogenously added IPP was performed. 
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These experiments show that active HMGR is important for stimulation of TCR γδ 
cells by Daudi and YMB-1 cells. Moreover, the data suggest that indeed 
phosphorylated metabolites generated in the mevalonate pathway are the 
stimulatory ligands for TCR Vγ9-Vδ2 cells. 
 
HMGR overexpressing cells are potent TCR γδ cells stimulators 
Transfected cells expressed high levels of HMGR as shown by 
intracellular staining with a specific HMGR mAb (Figure 13) 
 
 
 
Figure 13. HMGR overexpression in transfected Daudi cells.  
Intracellular level of HMGR protein in HMGR-trasfected (bold line) or non-transfected 
(thin line) Daudi cells was determined by staining with anti-HMGR specific mAb. Control 
staining was performed with irrelevant mAb (dotted lines). 
 
These cells were used as APC in TCR γδ activation assay. The capacity to 
stimulate TCR γδ cells by Daudi-HMGR transfected cells was significantly 
increased as compared to the wild type Daudi cells (Figure 14). Moreover, when 
APC were treated with suboptimal doses of MEV, T cell activation was strongly 
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reduced. The complete inhibition, in case of Daudi-HMGR cells, was achieved 
only when MEV was added at least 12 h before the assay (Figure 14). HMGR-
transfected cells might require longer incubation with inhibitor since the HMGR 
protein level in these cells is increased and also mevalonate metabolites might 
reach higher concentrations. 
 
 
 
Figure 14. HMGR overexpression increases TCR γδ cell activation. 
HMGR-transfected (closed bars) or wt Daudi cells (open bars) were used as APC in 
TCR γδ stimulation assay. A suboptimal dose (10 µM) of MEV was added 2, 6 or 12 h 
before incubation with T cells. Stimulation with exogenouse IPP was used as positive 
control. 
 
 
Nitrogen-containing bisphosphonates treated APC activate TCR γδ cells  
The involvement of endogenous mevalonate pathway in the generation of 
TCR γδ stimulatory ligands was further investigated in a series of experiments 
with nitrogen-containing bisphosphonate drugs (nBP). These drugs have a 
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capacity to inhibit farneslypyrophosphate-synthase (FPP-synthase), (Thompson 
et al., 2002), (one of the enzymes in the mevalonate pathway, Figure 5B) and in 
vitro lead to accumulation of IPP/DMAPP (Bergstrom et al., 2000) metabolites 
that are able to activate TCR γδ cells when exogenously added (Selin et al., 
1992; Burk et al., 1995; Tanaka et al., 1995). 
We tested two structurally different nBP, zoledronate (ZOL) and pamidronate 
(PAM) in TCR γδ activation assay. We compared their effect with etidronate, a 
non-nBP compound that does not block FPP-synthase (Bergstrom et al., 2000; 
Dunford et al., 2001). APC treated with either ZOL or PAM, but not with 
etidronate, stimulated TCR γδ cells very efficiently (Figure 15). 
 
 
 
Figure 15. nBP treated APC stimulate TCR γδ cells. 
Daudi cells treated with increasing doses of ZOL () or PAM () or etidronate () were 
used as APC in TCR γδ activation assay.  
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These results show that not all compounds containing a phosphate group induce 
stimulation of TCR γδ cells and confirm previous studies performed with other 
nBP (Kunzmann et al., 2000; Das et al., 2001b).  
 
nBP have different mechanisms of action than IPP 
When stimulated with exogenously added phosphorylated metabolites 
TCR γδ cells require their permanent presence during the assay. When IPP is 
added to APC and then cells are washed, the capacity of APC to stimulate TCR 
γδ cells is lost. Presumably the activatory compounds are not stably associated 
on the surface of APC (Morita et al., 1995). We tested whether the same rule 
applies to nBP treated cells.  
THP-1 cells were pulsed for 2 h with ZOL, PAM or IPP and then extensively 
washed before adding TCR γδ cells. After pulsing with ZOL or PAM, but not with 
IPP, THP-1 cells strongly activated TCR γδ cells (Figure 16). In control 
experiments all compounds were stimulatory when they were kept during the 
whole assay (Figure 16). 
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Figure 16. nBP drugs can be pulsed on APC. 
THP-1 cells were pulsed for 2 h (open bars) with nBP or IPP and used for stimulation of 
TCR γδ cells. Overnight incubation (closed bars) with ZOL or PAM was used as a 
positive control. 
 
 
These data show that nBP behave differently from IPP and confirm previous 
observations that nBP can be pulsed on primary monocytes and on different 
tumor cell lines (Das et al., 2001b; Kato et al., 2001). 
We compared the kinetics of T cell activation by ZOL- or PAM-treated 
APC. Daudi cells were pulsed with ZOL or PAM for various periods of time before 
adding TCR γδ clone. ZOL treated APC reach 80% of maximal activation already 
after 2 h pulse (Figure 17). Nonetheless, cells treated with PAM reached the 
same stimulatory capacity after prolonged pulsing time.  
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Figure 17. ZOL induces TCR γδ cells faster activation than PAM. 
Daudi cells pulsed for 2 h either with ZOL () or PAM () were used to stimulate TCR 
γδ cells. 
 
 
These results implicate that ZOL is more potent inhibitor of FPP-synthase 
(Dunford et al., 2001) but both compounds do not differ in their mechanism of 
action.  
 
nBP require internalization for their activity 
The fact, that APC treated with nBP remain stimulatory after pulsing and 
washing of the compounds raised the question whether their internalization into 
APC is mandatory for activation of TCR γδ cells. Therefore, to address this issue 
Daudi cells were pulsed with ZOL in conditions that inhibit pinocytosis and 
receptor mediated endocytosis (Schlegel et al., 1981; Wilcox et al., 1982). 
Pulsing the cells with ZOL either at 4°C (Figure 18A) or in the presence of 
monensin (Mon), (Figure 18B) strongly inhibited activation of TCR γδ cells. In 
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control experiments APC treated at 4°C before ZOL addition did not lose the 
capacity to stimulate T cells (Figure 18A) and Mon did not affect activation with 
exogenously added IPP (Figure 18B). 
 
 
 
Figure 18. ZOL requires cellular internalization by APC, to induce TCR γδ cells 
activation. 
(A) Daudi cells were pulsed with ZOL either at 4 or 37°C and used in TCR γδ activation 
assay. To exclude inhibitory effect of incubation at 4°C ZOL was added back to the 
control group. 
(B) Daudi cells after pulsing with ZOL in the absence or presence of Mon were used to 
stimulate TCR γδ cells. Stimulation with exogenously added IPP was used as a positive 
control.  
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In order to further proof that nBP are internalized we pulsed Daudi cells 
with 14C-labeled ZOL under similar experimental conditions and in the presence 
of NaN3 in order to block ATP-dependent active uptake during pulsing time. 
Incubation either at 4°C or in the presence of monensin completely abolished the 
uptake of 14C-ZOL (Figure 19). 
 
 
 
Figure 19. Intracellular uptake of 14C-labeled ZOL by Daudi cells. 
Daudi cells were pulsed with 14C-labeled ZOL at 37°C in the absence or presence of 
Mon. Incubation at 4°C was performed in order to exclude surface binding of ZOL. 
 
These data demonstrate that nBP need internalization in order to become active. 
This is another difference between this class of compounds and IPP which is 
active without being internalized (Morita et al., 1995). 
 
nBP induce accumulation of endogenous TCR γδ ligands  
 The previous experiments strongly suggest that nBP induce modification 
in APC, which then become stimulatory for TCR γδ cells. Therefore, we 
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investigated the hypothesis that nBP induce intracellular accumulation of 
stimulatory metabolites. 
In order to further examine this hypothesis we performed TCR γδ cells stimulation 
by Daudi cells pulsed with ZOL in the presence of MEV. The complete inhibition 
of TCR γδ cells activation was observed when ZOL was added simultaneously 
with MEV (Figure 20). One hour interval between ZOL and MEV addition reduced 
the inhibitory effect to 50%. When MEV was added 3 h after ZOL the inhibition 
was not observed anymore suggesting that accumulation of TCR γδ cells 
stimulatory ligands had already taken place.  
 
 
 
Figure 20. MEV inhibits T cell activation induced by nBP when added simultaneously 
with ZOL. 
Daudi cells were pulsed with ZOL in the presence of MEV which was added at indicated 
time points after ZOL. Daudi cells were washed and used to stimulate TCR γδ cells. 
 
This result suggests that TCR γδ cells stimulatory ligands, generated in the 
mevalonate pathway, must be downstream products of HMGR and upstream 
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intermediates of FPP-synthase. Therefore activatory metabolites are most likely 
prenylated pyrophosphates or mevalonic acid pyrophosphate derivatives. 
 
Identification of metabolites important for tumor cell recognition 
In order to identify stimulatory metabolites Daudi cells extracts were used 
to generate them in vitro utilizing mevalonic acid, the first metabolite in 
mevalonate pathway produced by HMGR. Purified products were treated with 
alkaline phosphatase and were tested in TCR γδ cells activation assay. The TCR 
γδ cell stimulatory capacity of generated ligands was sensitive to alkaline 
phosphatase treatment (Figure 21).  
 
 
 
Figure 21. The stimulatory ligands present in Daudi extracts are alkaline phosphatase 
(AP) sensitive. 
Daudi cell extracts were treated with AP and then tested for the capacity to activate TCR 
γδ cells. IPP treated identically was used as a positive control for AP activity. 
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In the next set of experiments Daudi cell extracts were incubated with 3H-
mevalonic and radioactive downstream products were detected in the HPLC 
fractions. The retention time obtained with Daudi cell extracts was identical as 
the reference 3H-labeled IPP (Figure 22A, B and C). All obtained HPLC fraction 
was tested in TCR γδ cells activation assay. The same fractions from the Daudi 
cell extracts (which elute at 15-16 min) were also capable to stimulate TCR γδ 
cells (Figure 22D).  
 
 
 
Figure 22. Mevalonate pathway metabolites are the intracellular Daudi ligands activating 
TCR γδ cells. 
(A) Profile of 3H-labeled compounds generated with Daudi cell extracts after addition of 
3H-mevalonic acid. 
(B) 3H-labeled IPP reference profile. 
(C) 3H-mevalonic acid reference profile. 
(D) Bioactivity of TCR γδ cells stimulatory ligands from Daudi cell extracts after addition 
of 3H-mevalonic acid. HPLC fractions were tested at final dilution 1:12 using THP-1 cells 
as APC in TCR γδ cells activation assay. 
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 To identify the exact chemical structure of the active compounds mass 
spectrometry analysis was performed on the most active fraction eluting at 15.5 
min (Figure 23). 
 
 
 
 
Figure 23. Identification of IPP in Daudi extracts by mass spectrometry. 
Mass spectrometry analysis of active HPLC fraction eluting at 15.5 min. The arrow 
indicates the mass of IPP. The insert shows the mass of reference IPP. 
 
The ion-spray mass spectrometry analysis of the HPLC-purified and TCR γδ 
stimulatory fraction confirmed the presence of a compound with the same mass 
as IPP. 
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Discussion 
 
The population of TCR γδ cells expressing TCR composed of Vγ9 and Vδ2 
chains is activated by small phosphorylated nonpeptidic metabolites of bacterial 
origin. In prokaryotes these stimulatory antigens are generated either in the MEP 
or mevalonate pathway of isoprenoids biosynthesis. Moreover TCR Vγ9-Vδ2 cells 
have also ability to recognize and eliminate certain lymphomas in vitro and in a 
SCID animal model in vivo (Fisch et al., 1990; Malkovska et al., 1992).  
Since mevalonate pathway is present in all eukaryotic cells we investigated the 
involvement of this pathway in generation of TCR γδ stimulatory ligands. 
Two tumor cell lines of different origin i.e. Daudi Burkitt’s lymphoma and 
YMB-1 solid breast carcinoma lose their capacity to activate TCR Vγ9-Vδ2 cells 
when treated with mevastatin a potent inhibitor of the HMGR catalytic site (Istvan 
and Deisenhofer, 2001). In addition treatment with endogenous metabolites, 7-
DHC and farnesol, which, facilitate HMGR degradation by negative feedback 
mechanism (Correll et al., 1994; Honda et al., 1998) reduced the level of 
endogenous HMGR and significantly inhibited TCR γδ activation. Upregulation of 
HMGR protein level, by overexpresion of the enzyme in Daudi cells, resulted in 
significant increase of TCR Vγ9-Vδ2 cells activation. These results indicate that 
active HMGR is important for generation of TCR γδ stimulatory ligands. 
Furthermore the involvement of endogenous mevalonate pathway in 
generation of phosphorylated antigens was investigated using nBP drugs which 
inhibit FPP synthase (Bergstrom et al., 2000). The treatment with nBP increases 
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the capacity of various cells types (including human primary lung fibroblasts) to 
activate TCR Vγ9-Vδ2 cells. All tested cell lines were also very stimulatory when 
exogenous IPP was added. Presentation of both exogenous and endogenous 
ligands by many different cell types indicates the involvement of non polymorphic 
molecule(s) with a broad tissue distribution. However, the fact that nBP, in 
contrast to IPP, can be pulsed on antigen presenting cells suggest that they differ 
in their mechanisms of action. Indeed we showed that nBP in order to be active 
require internalization. Moreover, the effect of nBP depends on active HMGR 
since it is blocked when cells are treated with MEV. These results suggest that 
nBP by blocking FPP, induce accumulation of mevalonate metabolites which are 
directly responsible for activation of TCR γδ cells. Further analysis revealed that 
these metabolites contain phosphate residue and their mass corresponds to the 
one of IPP. However, since detected IPP originates from an in vitro enzymatic 
assay, it cannot be excluded that in vivo other phosphorylated metabolites of the 
mevalonate pathway might be involved in TCR γδ activation. Therefore, we can 
conclude that detection of certain tumors by TCR Vγ9-Vδ2 cells is mediated by 
cognate recognition of endogenous metabolites generated in these tumor cells. 
Currently we cannot discriminate whether in tumor cells generation of TCR 
γδ activatory ligands occurs due to the increased activity of HMGR, or due to the 
impairment in the metabolite utilization, or both. Nonetheless, the recognition of 
cells with altered mevalonate pathway that overproduce phosphorylated 
metabolites may allow the immune system to target the cells with metabolic 
abnormalities. Importantly, dysregulation of mevalonate pathway leading to TCR 
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γδ cells activation can be pharmacologically induced with nBP providing a novel 
approach in tumor immunotherapy. 
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Part  2 
 
Transient dysregulation of the mevalonate pathway during early 
bacterial infection leads to TCR Vγ9-Vδ2 cells activation 
 
Elevated levels of TCR Vγ9-Vδ2 cells in the peripheral blood of patients 
(Morita et al., 1999) and macaques (Shen et al., 2002) have been described in a 
variety of bacterial and protozoan infections. These TCR γδ cells have pro-
inflammatory functions and it has been suggested that they participate in 
protective immunity (Morita et al., 1999). 
The expansion of TCR Vγ9-Vδ2 cells has been associated with the 
production of HMB-PP by microbes. Indeed, infections displaying in vivo 
expansion of TCR γδ cells are caused by microorganisms that also utilize the 
MEP pathway (Eberl et al., 2003). The possibility that TCR Vγ9-Vδ2 cells are 
stimulated by HMB-PP during infections has not yet been tested experimentally 
and it has been assumed that only APC infected with HMB-PP-producing 
microorganisms stimulate TCR γδ cells (Eberl et al., 2003). Here we investigate 
the mechanisms by which TCR γδ cells get activated by bacteria-infected APC.
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Results 
 
Stimulation of TCR Vγ9-Vδ2 cells by bacteria-infected APC is MEP pathway 
independent 
Two types of human cells, namely freshly isolated CD14+ monocytes and 
immature dendritic cells (DC) were infected and used as antigen-presenting cells 
(APC) to stimulate TCR Vγ9-Vδ2 T cells. Infecting agents were the gram-negative 
Escherichia coli, which utilizes the MEP pathway, or the gram-positive 
Staphylococcus aureus, which lacks the MEP pathway and utilizes the 
mevalonate pathway (Morita et al., 2000), (Table 1). TCR Vγ9-Vδ2 cells were 
efficiently activated by infected APC (Figure 24A). The activation was inoculum-
dependent and at a multiplicity of infection (MOI, bacteria: APC) of 0.1 an 
efficient stimulation could already be observed when using both bacteria species. 
Surprisingly, monocytes and DC infected with S. aureus were also strong 
stimulators, showing that MEP pathway negative bacteria also have the capacity 
to activate TCR γδ cells. MHC class II-deficient APC infected with  
S. aureus were also stimulatory, thus ruling out a superantigen effect during 
infection with these bacteria (Rust et al., 1990), (Figure 24B).  
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Figure 24. E. coli- and S. aureus-infected APC stimulate TCR γδ cells. 
(A) Monocytes () and DC () were infected with E. coli or S. aureus. MOI 
(bacteria/APC) is expressed on the X axis, IFNγ (ng/ml ± SD) released by TCR γδ cells 
on the Y axis.  
(B) S. aureus-infected APC activate TCR γδ cells without superantigen effect. Raji cells 
(open bars) and RJ 2.2.5 cells (closed bars), a MHC class II-deficient Raji mutant, were 
infected (MOI = 3) with E. coli or S. aureus and used as APC. 
 
 
The stimulatory effect was TCR γδ cell specific (Figure 25A) because, 
upon infection with the two bacterial strains of APC expressing the appropriate 
restriction molecules, TCR αβ peptide-specific and class II-restricted cells (Figure 
25B) or TCR αβ lipid-specific and CD1-restricted cells (Figure 25C) were not 
activated (Figure 25A, 25B and 25C). 
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Figure 25. Bacteria infected APC specifialy activate TCR γδ cells. 
(A and B) THP-1 or (C) CD1b-transfected THP-1 were infected with E. coli or S. aureus 
(MOI = 0.3) and used as APC to stimulate T cells. (A) TCR γδ cells were activated by 
bacteria-infected APC and also when exogenous IPP (10 µM) was added (Ag). 
(B) TCR γδ MHC class II-restricted cells specific for M. tuberculosis H37Ra protein 
antigen (Ag) responded only to heat-killed M. tuberculosis. (C) TCR γδ CD1b-restricted 
cells specific for the Ac2SGL sulfoglycolipid (Ag) responded only to APC presenting 
Ac2SGL. 
 
 
Endogenous mevalonate pathway is involved in generation of TCR γδ 
ligands during infection 
The strong stimulation observed when using APC infected with low 
numbers of bacteria raised the question of whether bacterial ligands are 
themselves responsible for TCR γδ cell stimulation. One possible explanation for 
these findings is that APC upregulate their mevalonate pathways during infection 
and accumulate endogenous TCR γδ-stimulatory ligands. To test this hypothesis, 
APC were incubated with zoledronate (ZOL), which induces accumulation of IPP 
by blocking the mevalonate pathway (this work, Figure 10), and infected with 
small numbers of bacteria, both at suboptimal doses, which are not stimulatory 
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alone. A strong synergistic effect was observed (Figure 26A), providing evidence 
that the stimulatory capacity of APC is positively modulated during bacterial 
infection. 
Investigations were performed to understand the mechanisms whereby 
bacteria facilitate stimulation of TCR γδ cells. The synergistic effect was 
dependent on the presence of active HMGR as is shown by the complete loss of 
activation in the presence of the HMGR inhibitor mevastatin (MEV), (Figure 26B). 
We also investigated whether upon infection APC upregulate their capacity to 
present antigen to and costimulate TCR γδ cells. This was ruled out by the lack of 
a significant increase of TCR γδ cell response to exogenous IPP when infected 
cells were used as APC (Figure 26C). 
 
 
 
Figure 26. Synergistic effect of bacterial infection and ZOL depends on active 
mevalonate pathway. 
(A) Infection and ZOL have synergistic effects. A-375 cells were treated with ZOL in the 
absence () or presence () of E. coli (MOI = 0.1). 
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(B) Synergistic effect of infection is HMGR-dependent. A-375 cells were treated with 
mevastatin (MEV) 2 h prior infection (MOI = 0.1) and addition of 2.5 µg/ml ZOL. 
(C) Infection does not increase the APC antigen presentation capacity. IPP presentation 
by A-375 cells in the absence () or presence () of E. coli (MOI = 0.1).  
 
Moreover we tested whether bacterial growth is modified in the presence of MEV 
and ZOL. None of the compounds influenced the growth of the bacteria used in 
the infection experiments (Figure 27) 
 
 
 
Figure 27. Mevalonate pathway modulators do not affect bacterial growth. 
ZOL or MEV were incubated with S. aureus or E. coli and bacterial growth was 
determined by CFU counts. 
 
Next the hypothesis was tested whether infection modulates HMGR 
activity in APC by using wild type or HMGR-transfected A-375 cells infected with 
either E. coli or with S. aureus (Figure 28A). HMGR-transfected APC showed a 
stronger stimulation capacity than wild type cells at all MOI and with both 
bacteria, suggesting the importance of an active endogenous mevalonate 
pathway. Moreover, MEV strongly reduced T cell activation in these experimental 
settings, thus revealing the importance of endogenous eukaryotic ligands (Figure 
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28B). MEV did not inhibit stimulation with exogenous IPP (Figure 28B), ruling out 
non-specific inhibitory effects.  
 
 
 
Figure 28. The mevalonate pathway is involved in the generation of the T cell stimulatory 
antigen during bacterial infection  
(A) HMGR-overexpression facilitates TCR γδ cell response during infection. HMGR-
transfected A-375 cells () infected with E. coli or S. aureus are more stimulatory than 
A-375 wt cells (). 
(B) Induction of endogenous ligands during bacterial infection. E. coli- or S. aureus-
infected monocytes (MOI = 0.3) were used as APC with or without MEV.  
 
Part 2, Results 
 72 
Bacterial infections modulate HMGR protein levels and phosphorylation 
state 
As HMGR is the rate-limiting enzyme of the mevalonate pathway, we 
investigated whether bacteria directly influence the intracellular levels and the 
function of HMGR. HMGR protein levels were evaluated by densitometry after 
immunoprecipitation and Western blotting of APC lysates. After infection with E. 
coli or with S. aureus (Figure 29A) a slight, but consistent, increase in the total 
levels of HMGR was already observable 1 h after infection, and was followed by 
a decline 24 h after infection. Analysis of HMGR gene transcription by semi-
quantitative RT-PCR showed that HMGR mRNA levels do not change 
immediately after infection and that they increase significantly after 24 h (Figure 
29B). This rapid increase in HMGR protein level at 1 h post infection, without a 
concomitant increase in mRNA levels, suggests that the regulation may occur 
through a reduced degradation of HMGR. 
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Figure 29. Bacterial infection modifies HMGR protein levels. 
(A) HMGR was immunoprecipitated from THP-1 cells infected (MOI = 1) with E. coli or S. 
aureus for 1, 2, 4 and 24 h (gentamycin was added after 4 h) and analyzed by Western 
blot. The bands indicated with the arrow correspond to intact HMGR (97 kDa). They 
were scanned and the values compared to the one obtained in uninfected cells (time 0). 
(B) Bacterial infection influences HMGR gene transcription at later time points. Semi-
quantitative RT-PCR analysis of HMGR (upper panel) was performed on THP-1 cells 
infected with E. coli (MOI = 1) for different time points. Serial 1:3 dilutions of cDNA are 
shown. As a control β-actin RT-PCR (lower panel) was performed. * indicates that the 
difference between time 0 and 24 h is significant (p<0.05). 
 
As dephosphorylated HMGR is more active and generates more 
mevalonate than phosphorylated forms (Omkumar et al., 1994; Istvan and 
Deisenhofer, 2000), the possibility that rapid HMGR dephosphorylation occurs 
during bacterial infection was investigated. HMGR was immunoprecipitated from 
E. coli- or S. aureus-infected cells as well as from control cells and detected by 
Western blotting by using a phosphoserine-specific mAb (Figure 30A). The 
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percentage of HMGR represented by phosphorylated HMGR was calculated in 
each time point. An ~40% reduction of phosphorylated HMGR was already 
observed in APC 1 h after infection. Levels of phosphorylated HMGR decreased 
to 25% after 2 h and returned to normal levels 12-24 h post infection (Figure 
30B), suggesting that there is a rapid increase of the HMGR enzymatic activity 
shortly after infection. This hypothesis is supported by the increased capacity of 
infected APC to stimulate TCR γδ cells, which peaked 5 h after infection and was 
reduced after 13 h (Figure 30C). 
 
 
 
Figure 30. Infection induces transient HMGR dephosphorylation and TCR γδ cell 
activation. 
(A) HMGR-transfected A-375 cells were infected (MOI = 10) with E. coli or S. aureus for 
30 min, then gentamycin was added for 30 min. HMGR protein was immunoprecipitated 
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and phosphorylation was analyzed by Western blot. Control total HMGR protein levels 
are shown in the lower panel. 
(B) HMGR phosphorylation is modulated during infection. HMGR-transfected A375 were 
infected with E. coli (MOI = 10) and HMGR phosphorylation and protein levels were 
analyzed. Results are expressed as a % of phosphorylated HMGR standardized for total 
HMGR signal in infected and uninfected cells (time 0, 100%). 
(C) Duration of APC stimulatory capacity after bacterial infection. DC were infected with 
E. coli at MOI 1 (), 0.3 (), 0.1 () or uninfected (). Gentamycin was applied after 3 
h and T cells added at the indicated time points. 
 
 
Increased PP2A activity leads to HMGR dephosphorylation induced by 
bacterial infection  
The mechanism for serine 872 dephosphorylation in HMGR was 
investigated by using phosphatase inhibitors. Within the serine/threonine 
phosphatase family, PP2A is an enzyme with an ubiquitous distribution, large 
abundance and broad specificity (Wera and Hemmings, 1995). We took 
advantage of okadaic acid (OA), and calyculin A (CA) drugs, which block PP2A 
activity (Favre et al., 1997) to determine whether PP2A is required for activation 
of TCR γδ cells. We could not use the bacteria infection model to stimulate TCR 
γδ cells because preincubation of APC with these drugs leads to altered 
phagocytosis (Zhang et al., 2000; Sosroseno et al., 2003). Therefore, Daudi 
cells, which stimulate TCR Vγ9-Vδ2 cells without addition of exogenous ligands 
(Fisch et al., 1990), were used. Daudi cells pretreated with OA and CA were no 
longer able to activate TCR γδ cells as revealed by Ca2+ mobilization in the T 
cells (Figure 31A), showing the requirement for active PP2A. Unspecific effects 
of phosphatase inhibitors on antigen presentation were ruled out by showing that 
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Daudi cells pretreated with ZOL (to stimulate the accumulation of endogenous 
ligands) maintain their capacity to induce T cells Ca2+ flux (Figure 31B). 
 
 
 
Figure 31. PP2A inhibitors block activation of TCR γδ. 
(A and B) Daudi cells treated with OA (dotted line), CA (thin line) or untreated (bold line), 
in the absence (A) or presence (B) of ZOL, were used to induce Ca2+-flux in TCR γδ 
cells. APC and T cells were mixed and immediately analyzed to detect the base line, 
then cells were removed, centrifuged to facilitate doublet formation and reapplied to the 
cytometer (arrow). The mean Ca2+-bound and unbound Indo-1 ratio in T cells forming 
doublets with APC is plotted on Y-axis versus time in X-axis. 
 
In order to confirm the activation of PP2A upon infection, we compared the 
enzymatic activity of PP2A as early as 2 h after inoculation of either E. coli or S. 
aureus (Figure 32) to that of uninfected cells. A significant increase was 
observed thus showing that upon bacterial infection, PP2A phosphatase is 
activated and suggesting participation in HMGR dephosphorylation. 
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Figure 32. PP2A activity is increased upon bacterial infection. 
Cell lysates from HMGR-transfected A-375 cells infected (MOI = 10) with E. coli or S. 
aureus for 2 h (30 min after infection gentamycin was added) were used to determine 
PP2A activity. Results are represented as % of PP2A activity. 100% was calculated for 
uninfected cells. Significant differences are indicated by *(p<0.05) or **(p<0.005). 
 
 
HMGR activity is increased during early times of bacterial infection 
To examine whether HMGR dephosphorylation and increased protein 
levels might be responsible for increased HMGR enzymatic activity, infected and 
control cells were lysed and the crude extracts were tested in vitro for their 
content of active HMGR, i.e. for the capacity to utilize the substrate 
hydroxymethylglutaryl-CoA (HMG-CoA), using NADPH as a co-substrate. The 
product of the reaction, mevalonic acid was monitored by liquid chromatography-
electrospray-mass spectrometry (LC-ESI-MS) after conversion into the more 
stable mevalonolactone (MVL), (Gerber et al., 2004). In preliminary experiments 
aimed at determining the enzyme kinetics we found that a 60 min enzymatic 
reaction was optimal to generate measurable metabolite without reaching a 
plateau, thus permitting exact MVL quantization (Figure 33A and 33B). In the 
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absence of NADPH, MVL was not detectable, confirming the specificity of the 
assay. A kinetic analysis showed that HMGR activity increases 1 h after infection, 
peaks at 4 h (40% increase in MVL production), and then declines at 24 h (Figure 
33C). 
 
 
 
Figure 33. HMGR activity increases in early bacterial infection. 
(A) Calibration curve of MVL. The area is calculated from the SIM of m/z 131 at 2.7 min. 
(B) Reaction kinetics of HMGR activity in THP-1 homogenate. Values represent 
duplicate measurements ± SD. 
(C) HMGR activity upon infection. THP-1 cells were infected with E. coli (MOI = 1) for 1, 
4 and 24 h (gentamycin was added after 4 h) or uninfected (time 0). Values represent 
duplicate experiments ± SD, 100% of MVL (1.229 µM ± 0.05 per 107 cells) is calculated 
on uninfected cells. Significant differences are indicated by * (p<0.05) or ** (p<0.01). 
 
 
Thus, the dephosphorylation of HMGR and its increased levels result in a 
transient, but high, upregulation of its enzymatic activity. 
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Activity of MVK, PMVK and MVD is not changed during bacterial infection 
 We next investigated whether bacterial infection also influences other 
enzymes in the mevalonate pathway. We tested the activity of the 3 enzymes 
that generate IPP downstream of HMGR in the pathway, i.e. mevalonate kinase 
(MVK), phosphomevalonate kinase (PMVK) and diphosphomevalonate 
decarboxylase (MVD), (Figure 5). The activity of each enzyme was determined in 
extracts from APC infected with E. coli and compared to control cells. Kinetic 
analysis of all three enzymes showed that in the activities remain unchanged 
between 1 and 24 h after infection (Figure 34A, 34B and 34C). 
 
 
 
Figure 34. Enzymatic activity of MVK, PMVK and MVD is not modified upon bacterial 
infection. 
(A) MVK, (B) PMVK and (C) MVD enzymatic activities upon infection. THP-1 cells were 
cultured for 1, 4 or 24 h (gentamycin was added after 4 h) in the presence () or 
absence () of E. coli (MOI=1). Values on the Y axis represent duplicate experiments ± 
SEM. 100% of each enzyme activity was calculated for 1 h cultured uninfected cells and 
corresponds to: 124.5±8 pmol/min/mg of total protein (2.85±0.5 x 105 cpm) for MVK, 
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157±19 pmol/min/mg of total protein (2.7±0.4 x 105 cpm) for PMVK, and 60±25 
pmol/min/mg of protein (0.9±0.2 x 105 cpm) for MVD. The observed changes are not 
statistically significant (p>0.05). 
 
 
Increased HMGR activity during bacterial infection is MyD88 independent  
The early events leading to upregulation of HMGR activity during infection 
were further investigated by testing the possible involvement of Toll-like 
receptors (TLRs) triggering. For this purpose, HMGR activity was investigated in 
DC from MyD88-deficient mice. Crude extracts from E. coli-infected MyD88-/- and 
wild type C57BL/6 DC were tested for their content of active HMGR by LC-ECI-
MS. A significant increase of HMGR activity in DC from both mice was already 
observed 1 h after infection, peaking at 4 h, and declining to normal levels after 
18 h (Figure 35), thus indicating that the upregulation of HMGR activity is 
MyD88-independent. 
 
 
 
Figure 35. The increase of HMGR activity after infection is MyD88-independent. 
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DC from MyD88-/- () or C57BL/6 () mice were infected with E. coli (MOI = 1) for 1, 4 
and 24 h (gentamycin was added after 4 h) or uninfected (time 0). Values on Y axis 
represent % of MVL production. 100% is calculated on C57BL/6 uninfected cells and 
corresponds to 0.4 µM of MVL per 107 cells. Significant differences are indicated by * 
(p<0.01). 
 
From these experiments we conclude that HMGR enzymatic activity is 
increased in a MyD88-independent manner after bacterial infection, while the 
activities of other enzymes involved in IPP generation are unchanged. 
Altogether these results point to the following chronological order of 
events occurring in bacteria infected cells. At the early time points of bacterial 
infection (1h) HMGR activity increases without concomitant increase of mRNA 
synthesis. Later on (24 h) the activity of HMGR is decreased and it is 
accompanied by an increase of mRNA levels. This suggests that HMGR 
feedback regulatory mechanism occurs. Immediately after infection bacteria-
infected cells augment PP2A phosphatase activity, increase the amounts of 
dephosphorylated and total HMGR, raise the production of TCR γδ-stimulatory 
ligands and acquire the capacity to stimulate TCR γδ cells, which then declines 
24 h post-infection (Figure 36). 
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Figure 36. Schematic representation of the correlation between HMGR function and 
TCR γδ cell response during the early phase of infection 
The various parameters measuring HMGR function in APC are expressed on the left Y 
axis as % of control represented by uninfected cells. The T cell response is expressed 
as INFγ release on the right Y axis.  
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Discussion 
 
 The selective expansion of TCR Vγ9-Vδ2 cells during infection with certain 
bacteria or parasites suggests that these T cells have a role in immune defense 
against pathogens. Whether endogenous or bacterial products stimulate TCR 
Vγ9-Vδ2 cells during infection was unknown. The discovery of HMB-PP, a 
metabolite product of the MEP pathway, as the most potent TCR γδ stimulatory 
ligand implicated its major role in T cell activation during microbial infection (Eberl 
et al., 2003). However, despite these compounds are active at low 
concentrations, it is questionable whether they reach the minimal concentration 
required for TCR γδ activation. Here we find that different phagocytic cell types, 
including freshly isolated monocytes and immature DC, immediately increase the 
production of mevalonate metabolites when infected with either MEP-positive 
E. coli or MEP-negative S. aureus bacteria and, as a consequence, acquire the 
capacity to stimulate TCR Vγ9-Vδ2 cells. 
The TCR γδ-stimulatory ligands are not produced by the bacteria themselves, but 
rather by the host mevalonate metabolic pathway. In fact infection of APC with 
very low MOI efficiently stimulates TCR γδ cells. It is possible that bacterial HMB-
PP represents an additional stimulatory ligand in a later phase of infection when 
large numbers of MEP-positive bacteria accumulate.  
In this study we show that bacterial infections naturally modulate the mevalonate 
metabolism of APC and suggest that endogenous mevalonate metabolites 
accumulating within infected cells stimulate TCR γδ cells. Upon infection of APC 
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with low doses of bacteria, and in the presence of small amounts of ZOL, both at 
suboptimal and inactive doses, there is a strong stimulation of TCR γδ cells. Thus 
bacterial infection has a synergistic activity on the ZOL effects. In addition, the 
treatment of infected APC with mevastatin prevents the generation of the cellular 
stimulatory ligands and inhibits TCR γδ cell activation. Therefore, the HMGR 
activity in APC sets the threshold of TCR γδ response to infection.  
Infection promotes two different mechanisms, both of which augment the function 
of this key enzyme. Firstly, there is a rapid rise in the HMGR protein levels within 
the first hour post-infection. Since there is no concomitant increase in HMGR 
mRNA levels, it is likely that HMGR protein rises as a consequence of its 
reduced degradation in infected cells. Secondly, infection also leads to increased 
amounts of the dephosphorylated form of HMGR, which is followed by enhanced 
enzymatic activity. This is in agreement with other studies showing that HMGR 
activity is negatively influenced by phosphorylation of serine 872 by AMP-
activated protein kinase (Omkumar et al., 1994; Istvan and Deisenhofer, 2000). 
Mass Spectrometric quantitative analysis confirmed that there was increased 
HMGR activity in infected phagocytic cells, as compared to non-infected cells. 
The early modifications in HMGR protein levels and dephosphorylated forms 
immediately precede maximal T cell activation, which shows a peak 4-8 h after 
infection in our experimental system. This suggests a direct correlation of the 
three phenomena, which appear in a temporally ordered fashion (Figure 36). The 
other enzymes involved in IPP synthesis (i.e. mevalonate kinase, 
phosphomevalonate kinase and diphosphomevalonate decarboxylase), do not 
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increase their activity upon infection, which confirms the key role of HMGR as the 
main regulatory enzyme in the mevalonate pathway (Goldstein and Brown, 
1990). 
Our attempts to outline the mechanisms leading to HMGR dephosphorylation 
indicate an increased activity of PP2A in the early phases of bacterial infection 
and suggest that HMGR is a PP2A substrate. Activity of this serine/threonine 
phosphatase is required to maintain the stimulatory capacity of Daudi cells, as 
shown by inhibition with PP2A-blocking drugs, and this reveals a previously 
unrecognized role of this phosphatase in stimulating TCR γδ cells. PP2A is 
probably involved in the production of TCR γδ stimulatory ligands and not in 
antigen presentation, as indicated by experiments with ZOL-treated Daudi cells. 
Indeed, these cells accumulate endogenous ligands and maintain a strong TCR 
γδ cell stimulatory capacity in the presence of PP2A inhibitory drugs. 
Previous studies have shown that other phosphatases, such as dual specificity 
phosphatases, are activated during innate immune responses (Liu et al., 2007). 
Importantly, these phosphatases are not active on serine as substrate as is the 
case with PP2A and therefore are not candidate to dephosphorylate HMGR in 
vivo. 
HMGR activation following infection is independent from the MyD88 pathway, 
thus implying that this phenomenon is not associated with microbial activation of 
Toll-like receptors which utilize MyD88. Whether, other adaptor proteins of innate 
immunity are involved in HMGR activation remains to be investigated. 
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Different stimuli, including cholesterol depletion (Goldstein et al., 2006), 
growth factors and insulin signaling (Demoulin et al., 2004; Nadeau et al., 2004) 
exposure to hypotonic media, and ER calcium depletion (Lee and Ye, 2004), 
have been reported to induce upregulation of HMGR transcription. Interestingly, 
HMGR gene transcription also increases after internalization of latex beads 
(Castoreno et al., 2005), which, to some extent mimics phagocytosis of bacteria. 
Moreover, membrane pore formation by the bacterial aerolysin toxin, leads to 
upregulation of HMGR transcription and to increased cholesterol synthesis as a 
defence mechanism facilitating membrane repair (Gurcel et al., 2006). Therefore, 
upregulation of mevalonate pathway occurs after a variety of cell stressing 
signals, as a result of increased HMGR gene transcription and enzymatic activity. 
Here we add a novel mechanism involving HMGR dephosphorylation and PP2A 
activation occurring during the early phases of infection. Whether the other 
physiological conditions which upregulate HMGR transcription also induce 
stimulation of TCR γδ cells has not been investigated. 
Overall these findings have revealed two important aspects relating to the 
manner in which infected cells activate TCR Vγ9-Vδ2 cells and therefore to the 
possible relevance of this T cell population in immune responses in vivo. Firstly, 
HMGR dephosphorylation and accumulation of endogenous (self) ligands is fast, 
being detectable within the first hour post infection. This rapid mechanism may 
contribute to the stimulation of TCR Vγ9-Vδ2 cell response during the very early 
stages of infection, when very low numbers of bacteria are present and when 
other bacteria-specific T cells are not available at the site of infection.  
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Another important issue is that the mevalonate dysregulation following infection 
is transient. This probably occurs because of the feedback regulation of both the 
mevalonate pathway and cholesterol metabolism, both of which are tightly 
controlled within cells (Goldstein and Brown, 1990). The temporary alteration of 
the mevalonate pathway is necessary to avoid continuous stimulation of TCR 
Vγ9-Vδ2 cells, which are very abundant and thus have to be activated with 
caution. Despite its short duration, the transient activation may explain the 
observed expansion of this TCR γδ population in the periphery during early post-
natal life (Parker et al., 1990). This could be the result of repeated infections 
naturally occurring in this age. 
Part 3, Results 
 88 
Part 3 
 
Multi-drug related protein 5 (MRP5, ABCC5) is involved in 
trafficking of phosphorylated mevalonate metabolites  
 
 The fact that TCR γδ cells are activated by endogenous mevalonate 
metabolites generated inside APC raised the question how these antigens are 
transported to cell surface in order to be presented to the T cells. Prenylated 
phosphorylated metabolites are polar molecules (Figure 6), and therefore a 
passive transportation through the cell membrane is very improbable despite 
their low molecular masses. Instead, it may be more likely an inside-out transport 
by a transmembrane transfer protein, whose activity is either ATP-dependent or 
driven by a concentration gradient. 
 
Results 
 
Transfer of TCR γδ stimulatory ligands 
 The hypothesis of ligand transfer was investigated using mouse cells that 
do not have the capacity to directly stimulate TCR γδ cell (De Libero et al., 1991; 
Kato et al., 2003) in co-culture with human dendritic cells (DC), that efficiently 
stimulate TCR γδ cells. The M12.4.1 mouse B cell lymphoma cell line, in which 
TCR γδ stimulatory ligands accumulation was induced by pulsing with 
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zoledronate (ZOL), were mixed with DC cells and used in T cells activation 
assay. We observed a significant increase of TCR γδ cells activation (Figure 37).  
  
 
Figure 37. Transfer of endogenously generated antigens from mouse to human cells. 
Mouse M12.4.1 cells pulsed with ZOL were mixed with DC cells and used to stimulate 
TCR γδ clone. As a control not treated M12.4.1 cells mixed with DC cells were used. 
 
 
We interpreted this result with a probable transfer of activatory metabolites from 
mouse cells to human APC.  
The synthesis of TCR γδ stimulatory ligands takes place in the cytoplasm 
(Hogenboom et al., 2004c; Hogenboom et al., 2004b; Hogenboom et al., 2004a) 
where they need to be transported from in order to be presented. Thus, we 
hypothesized that the transport through the membrane of phosphorylated 
antigenic metabolites is mediated by a transporter protein located at the cell 
surface. 
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Involvement of ATP-binding cassette transporter-C (ABC-C) in transport of 
the TCR γδ ligands 
In order to further investigate the protein mediating the transmembrane 
transport for TCR γδ ligands, a series of drugs inhibiting different transport 
proteins were used to block TCR γδ cell activation. The main targets of our 
investigation were the: ATP-binding cassette transporters (ABC), the 
monocarboxylate transporters (MCT) and the inorganic transporters. In addition, 
we also considered different classes of ATPases in our studies. 
Firstly, we established a TCR γδ assay in the presence of both APC 
accumulating endogenous mevalonate metabolites and drugs known as 
inhibitors of different classes of transporters. Table 4 lists the drugs used in the 
assays and their target transporters. 
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Compound Inhibited transporter 
Isopentenol 
Geraniol 
Farnesol 
Transporter for IPP/GPP/FPP? 
Foscarnet inorganic phosphate transporter 
Lactate 
Phenylpyruvate 
Phloridzin 
DIDS 
various MCT 
MCT1 
various MCT 
MCT2/MCT4/ABC??, irreversible chloride antiporter inhibitor 
ARL-67156 
β,γ−MAT 
Oligomycin 
Omeprazol 
Bafilomycin A1 
Ouabain  
ecto-ATPase inhibitor 
ecto-ATPase inhibitor 
mitochondrial F-type ATPase inhibitor, intracellular ATP-depletor 
gastric H+-ATPase inhibitor 
V-type ATPase inhibitor 
Na/K transport ATPase inhibitor 
Glybenclamide 
PSC-833 
PKF-274 
Niflumic acid 
Quercetin 
Sulfinpyrazone 
Benzbromarone 
Probenecid 
Methotrexate 
MK-571  
MDR1, MRP2, OATP1/2, SUR1/2 
MDR1, MDR2, many MRP 
MDR1, MDR2, many MRP 
MCT1, CFTR 
MCT1, MDR1, many MRP 
MRP1-5 
MRP1-5 
MRP1, 2, 3 
MRP1, 2, 3, MRP4? 
MRP1, 2, 4, 5 
 
Table 4. List of tested compounds with indicated groups of inhibited transporters. 
4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS), multi-drug resistance protein 
(MDR), multi-drug related protein (MRP), organic anion-transpoting polypeptide (OATP), 
sulfonylurea receptors (SUR), cystic fibrosis transmembrane conductance regulator 
(CFTR).  
 
Endogenous antigens in Daudi cells were increased by treatment with 
ZOL and in some experiments also with alkylamines (sec-butylamine, SBA, 
Figure 9). In control experiments activation in the presence of exogenously 
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added phytohemagglutinin (PHA) and activation of a CD1a-restricted TCR αβ 
clone was performed to exclude drug toxicity. Specific inhibition of TCR γδ 
activation was considered when activation with PHA or activation of TCR αβ 
clone was not affected. When drugs showed to be toxic when kept continuously 
in culture during entire assay, pulsing experiments were performed. All drugs 
were used at concentrations shown to be active in the literature. The percentage 
of inhibition of T cell activation was calculated for each tested drug considering 
the response in the absence of drugs as 100% (Table 5).  
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                     TCR γδ                                   TCR αβ  
  ZOL SBA IPP PHA Ag 
Drug Dose % of inhibition % of inhibition 
Isopentenol 200 µM 0 ND 0 0 ND 
Geraniol 40 µM 0 ND 0 0 ND 
Farnesol 20 µM 0 ND 0 0 ND 
Foscarnet 300 mM 0 0 0 0 0 
Lactate 100 µM 0 ND 0 0 ND 
Phenylpyruvate 100 µM 0 ND 0 0 ND 
Phloridzin 100 µM 0 ND 0 0 ND 
DIDS 300 µM 40 40 20 15 0 
ARL-67156 100 µM 0 0 0 0 0 
β,γ−MAT 300 µM 0 0 0 0 0 
Oligomycin 100 µg/ml 30 50 20 10 0 
Omeprazol 30 µg/ml 0 0 0 0 0 
Bafilomycin A1 100 nM 0 0 0 0 ND 
Ouabain 30 µM 0 0 0 0 0 
Glybenclamide 100 µM 0 0 0 0 0 
PSC-833 100 µM 100 100 70 40 35 
PKF-274 100 µM 100 100 75 45 40 
Niflumic acid 100 µM 0 0 0 0 0 
Quercetin 100 µM 30 40 10 0 0 
Sulfinpyrazone 10 mM 95 95 10 0 ND 
Benzbromarone 100 µM 65 80 40 0 ND 
Probenicid 3 mM  0 0 0 0 0 
Methotrexate 100 µM 0 0 0 0 0 
MK-571 300 µM 50 50 30 10 10 
 
Table 5. List of drugs with doses used in the TCR γδ and TCR αβ activation experiments.  
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Specific inhibition of TCR γδ cells activation was determined by comparing activation in 
the absence and presence of the drug, (ND, not determined). 
 
 The activation of TCR γδ cells was not affected when isopentenol, geraniol 
or farnesol, the alcohol analogs of IPP, GPP and FPP, respectively, were used. 
This suggests that the putative transporter recognizes the phosphate group 
which is present in active ligands (Pfeffer et al., 1990; Constant et al., 1994; 
Schoel et al., 1994; Tanaka et al., 1994). Therefore, the inhibitors of inorganic 
phosphate transporters, foscarnet (Yusufi et al., 1986; Timmer and Gunn, 1998), 
and inhibitors of MTC, lactate, phloridzin, phenylpyruvate (Halestrap and Price, 
1999), were tested. These compounds also did not show inhibition of TCR γδ 
cells activation. In contrast, two inhibitors of ABC transporters, PSC-833 and 
PKF-274, preferentially decreased activation of TCR γδ cells induced by ZOL or 
SBA. These findings indicated involvement of the protein(s) from the ABC-
transporters family in the TCR γδ activation. 
PSC-833 and PKF-274 drugs, which were chemically designed to inhibit multi-
drug resistant protein 1 (MDR1), (Boesch et al., 1991; Lum et al., 1993), a 
member of the B subfamily of ABC transporters, also inhibit other ABC 
transporters (Paul et al., 1996). Therefore, their broad activity does not allow 
discrimination of the transporter involved in TCR γδ cells activation.  
We have found two other drugs, sulfinpyrazone and benzbromarone, that 
specifically inhibit TCR γδ cells activation. The fact that these drugs inhibit 
various anion transporters belonging to the ABC family (Bakos et al., 2000; Evers 
et al., 2000) supported the hypothesis that the transporters involved in TCR γδ 
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activation recognize the anionic part of the stimulatory ligands. Additionally we 
found specific inhibition in the presence of quercetin, an inhibitor of ABC-C 
transporters (Walgren et al., 2000). Therefore, we narrowed our studies to the 
subfamily C of ABC transporters.  
This subfamily is composed of 12 characterized members: 9 multi-drug related 
proteins (MRP1-9), two sulfonylurea receptors (SUR1/2) and a cystic fibrosis 
transmembrane conductance regulator (CFTR). The MRPs studied so far, 
MRP1-8, are all organic anion pumps but they differ in substrate specificity and 
tissue distribution. CFTR is a chloride channel (Schwiebert et al., 1999) and 
SURs are the regulatory subunits of the ATP- sensitive potassium (KATP) channel 
(Aguilar-Bryan et al., 1998). Table 6 lists the members of the ABC-C family of 
transporters, their chromosomal localization, tissue distribution and substrate 
specificity. 
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Name (other 
nomenclature) 
Chromosomal 
localization 
Tissue distribution Substrate  
 
MRP1 (ABCC1) 
 
16p13.12-13 
 
ubiquitous 
 
GSH conjugates, organic 
sulfate and monoglutamate 
 
MRP2 (ABCC2) 10q23-24 liver, kidney, gut GSH conjugates, organic 
sulfate and monoglutamate  
 
MRP3 (ABCC3) 17q21.3 liver, adrenals, 
pancreas, kidney, gut, 
gallbladder 
bile salt (and conjugates), 
glucuronides, GSH 
conjugates 
 
MRP4 (ABCC4) 13q31-32 prostate, lung, muscle, 
pancreas, testis, 
ovary, bladder, 
gallbladder 
nucleoside-based drugs, 
conjugated steroids 
MRP5 (ABCC5) 3q27 ubiquitous nucleoside monophosphate 
analogs, cyclic nucleotides 
MRP6 (ABCC6) 16p13.1 liver, kidney acidic peptide 
CFTR (ABCC7) 7q31.2 lung, gut, many 
epithelial tissues 
 
SUR1 (ABCC8) 11p15.1 pancreas  
SUR2 (ABCC9) 12p12.1 hart and skeletal 
muscles, with low 
levels in all other 
tissues 
 
MRP7 (ABCC10) 6p21 ubiquitous (low) GSH and glucuronide 
conjugates 
 
MRP8 (ABCC11) 16q11-12 liver, lung, kidney, 
number of fetal tissues 
cyclic nucleotides 
MRP9 (ABCC12) 16q11-12 Testis, pancreas, brain unknown 
 
Table 6. List of members of ABC transporter subfamily C indicating: chromosomal 
localization (Dean et al., 2001), tissue distribution (Kool et al., 1997; Yabuuchi et al., 
2001; Bera et al., 2002) and examples of transported substrates (Borst et al., 2000; 
Chen et al., 2003; Borst et al., 2006).Glutathione (GSH). 
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Since TCR γδ cells are activated by many cell types from different tissue 
origin (Table 3), we assumed that the transporter involved in the antigen 
presentation has rather broad tissue distribution. Therefore, we reduced the 
number of candidate ABC-C transporters to those that are ubiquitously 
expressed. Furthermore, we excluded CFTR as a candidate because, niflumic 
acid, a potent inhibitor of CFTR (Scott-Ward et al., 2004) did not affect the 
activation of TCR γδ cells. We also eliminated MRP7 due to its low level of 
expression and our investigation focused on MRP1, MRP4 and MRP5. 
The MK-571, an analog of leukotriens which specifically inhibits the transport 
activity of MRP1, MRP4 and MRP5 (Reid et al., 2003) reduced the activation of 
TCR γδ cells. However, other drugs which inhibit only MRP1, such as probenicid 
and methotraxate (Bakos et al., 2000) did not affect TCR γδ cell activation. Thus, 
we concluded that MRP1 is not responsible for IPP transport.  
These results narrowed the studies to MRP4 and MRP5. Importantly, the tissue 
distribution of MRP5 was described as ubiquitous while MRP4 has been found in 
many but not all tissues (Kool et al., 1997). To further discriminate between 
MRP4 and MRP5, a real-time quantitative PCR analysis was performed to 
compare the mRNA levels of these two transporters in cell lines from various 
tissues (Table 7), which all stimulate TCR γδ cells when pulsed with ZOL. 
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Cell line MRP4 MRP5 
A-375 + + 
A-431 - + 
CEM 1.3 + + 
Colo-201 + + 
Daudi - + 
HEP G2 + + 
HL-60 + + 
HuH6 + + 
K562 + + 
 
Table 7. MRP4, and MRP5 mRNA expression in different cell lines. 
+, gene product was detected; -, no gene product. 
 
The MRP5 mRNA was detected in all tested cell lines, while MRP4 mRNA was 
absent in A-431 and Daudi cells. Since Daudi and A-431cells, after pulsing with 
ZOL and SBA, are very strong activators of TCR γδ cells we excluded MRP4 and 
focused on MRP5 as a candidate transporter of endogenous antigens. 
 
MRP5 overexpression increases stimulation of TCR γδ cells 
In order to investigate the hypothesis that MRP5 is responsible for the 
transport of stimulatory ligands, a Daudi cell line overexpresing MRP5 protein 
was generated. The capacity to stimulate TCR γδ cells by Daudi MRP5- 
transfected cells was significantly increased as compared to the wild type Daudi 
cells (Figure 38). 
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Figure 38. MRP5 overexpression increases TCR γδ cells activation. 
MRP5-transfected (closed bars) or wt Daudi cells (open bars) were used as APC in TCR 
γδ cells stimulation assay. 
 
To further investigate the effect of MRP5 overexpression on TCR γδ cells 
activation we transfected A-375 cell line, that requires treatment with ZOL in 
order to become stimulatory, with MRP5 gene and used them as APC (Figure 
39A, 39B and 39C). 
We found that MRP5 overexpression in APC facilitates not only presentation of 
endogenous antigens, accumulating after pulsing with ZOL (Figure 39A), but also 
improves presentation of exogenously added IPP (Figure 39B). As control we 
used the A375 MRP5-transfected cells to present peptide to MHC class I 
restricted T cells. We found that, the stimulatory effect of MRP5 was TCR γδ cell 
specific (Figure 39C) since presentation to the TCR αβ MHC class I restricted 
cells was not affected. 
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Figure 39. MRP5 participates in the transport of endogenous and exogenous TCR γδ 
ligands. 
(A) MRP5 overexpression facilitates TCR γδ cells activation by ZOL treated APC. MRP5 
transfected A-375 cells () stimulate TCR γδ more efficiently than A-375 wt cells (). 
(B) Exogenously added IPP is better presented by MRP5 transfected A-375 cells () 
than A-375 wt cells (). 
(C) MRP5 ovexpression does not influence stimulation of MHC class I restricted, Mart 
peptide specific TCR αβ clone. MRP5 transfected A-375 cells () and A-375 wt cells () 
were used as APC. 
 
 
MRP5 downmodulation affects stimulation of TCR γδ cells 
 In order to further confirm the involvement of MRP5 in the presentation of 
TCR γδ stimulatory ligands we knocked down the MRP5 protein and performed 
antigen presentation experiment. We generated four different small hairpin RNA 
(shRNA) interference constructs targeting MRP5 mRNA. A-375 cells were 
transfected with each of these constructs and were used as APC in TCR γδ 
activation experiments. We found that A-375 cells transfected with MRP5 shRNA 
interference constructs, but not with control firefly luciferase shRNA interference 
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constructs (Ff1), stimulated TCR γδ cells less efficiently than wt cells. The 
decrease in T cell activation was observed when APC were treated with ZOL 
(Figure 40A) or IPP (Figure 40B).  
 
 
 
Figure 40. MRP5 gene specific silencing alters stimulation of TCR γδ cells. 
(A and B) A-375 wt () cells and A-375 cells transfected with MRP5 specific shRNA 
interference silencing constructs pCMV_42 (), pCMV_1501 (), pCMV_2526 (), 
pCMV_3344 () or with irrelevant shRNA silencing construct Ff1 () were used as APC 
in endogenous (A) and exogenous (IPP) antigen presentation assays.  
 
The MRP5 shRNA interference construct pCMV_3344 had the strongest 
inhibitory capacity. Therefore, we used cells transfected with this construct in 
additional antigen presentation assays utilizing two other TCR γδ clones (Figure 
41). We found that knocking down of MRP5 completely inhibited presentation of 
endogenous ligand and strongly reduced presentation of exogenous IPP. 
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Figure 41. Presentation of endogenous and exogenous antigens TCR γδ clones (G2B9 
and G2C19). 
The percentage of T cell response induced by A-375 wt (100%, open bars), A-375 Ff1 
(dashed bars) or A-375 3344 (closed bars) cells treated either with ZOL (2.5 µg/ml) or 
IPP (2.5 µM). 
 
Knocking down of MRP5 mRNA in APC decreased TCR γδ cells activation 
regardless whether the antigen was induced inside APC by ZOL or was added 
from outside as IPP. The inhibition was TCR γδ specific since presentation of 
Mart peptide to the TCR αβ Mart-specific clone was not altered (Figure 42). 
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Figure 42. Presentation of Mart peptide to the TCR αβ clone.  
A-375 wt () cells and A-375 cells transfected with MRP5 shRNA interference 3344 () 
or Ff1 () irrelevant shRNA interference were used as APC. 
 
Taken together these data strongly suggest that MRP5 is the transporter involved 
in transfer TCR γδ stimulatory ligands generated in the mevalonate pathway.  
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Discussion 
 
The fact that intracellular metabolites activate TCR Vγ9-Vδ2 cells raised 
the question of how they are transported to the cell surface in order to establish a 
cognate interaction with TCR. One possibility could be that inside APC, 
mevalonate ligands bind to a dedicated presenting molecule and then are 
transported on the cell surface. Thus it would resemble the biology of MHC-
peptide and CD1-lipid complexes. However, the inability of IPP to bind to putative 
antigen-presenting molecules in a stable manner (IPP cannot be pulsed, Figure 
16) makes this mechanism unlikely. If this would be the case, we might speculate 
that the antigen presenting molecule is loaded intracellularly, forms immunogenic 
complexes with mevalonate metabolites in a stable manner, and then traffick on 
the cell surface, where ligands are degraded or dissociate with a very fast 
kinetics. 
Another possibility is that the mevalonate ligands are translocated across 
membranes by specific transporter proteins. Indeed, the polarity and high charge 
of pyrophosphorylated metabolites make unlikely a passive diffusion through 
membranes. 
 Here we identified MRP5, a member of ABC-C transporter family, as a 
protein required for activation of TCR Vγ9-Vδ2 cells. MRP5 is a multispecific 
organic anion pump which transports nucleotide analogs (Jedlitschky et al., 2000; 
Wijnholds et al., 2000). This protein has 12 transmembrane helices in each of 
two membrane spanning domains forming P-glycoprotein-like core (Persson and 
Argos, 1994; Belinsky et al., 1998). Therefore, together with MRP4 and MRP8, 
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MRP5 differs from other MRP proteins which contain additional transmembrane 
domain (TMD0) composed of five transmembrane helices (Figure 43), (Borst et 
al., 1999; Guo et al., 2003; Ballatori et al., 2005).  
 
OUT
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NBD1 NBD2
NBD1 NBD2
TMD0 L0 Pgp-like core
MRP1,2,3,6 and 7
MRP4,5,8 and 9?
COOH
COOHNH2
NH2
 
 
Figure 43. Schematics showing structures of MRP, adapted from (Borst et al., 2000; 
Kruh et al., 2007).  
The common part of all MRP is the linker domain (L0) and P-glycoprotein (Pgp)-like core 
composed of transmembrane domains with nucleotide binding domains (NBD1 and 2). 
MRP4, 5, 8 and possibly MRP9 are lacking extra N-terminal transmembrane domain 
(TMD0).  
 
Blocking of MRP5 significantly inhibits activation of TCR γδ cells when 
APC are loaded with ZOL or alkylamines and slightly decrease presentation of 
exogenous IPP but does not affect activation induced by PHA. Moreover, we also 
found that tumor cells overexpressing MRP5 acquire stronger TCR γδ stimulatory 
capacity than control cells when they present both endogenous and exogenous 
antigens. The fact that MPR5 improves also presentation of exogenous IPP can 
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be explained with two mechanismis i) MRP5 might participate in the loading of 
putative antigen presenting molecule directly on the cell surface or ii) IPP might 
partially internalized inside APC and then reexpressed on the cell surface with 
the help of MRP5. 
The involvement of MRP5 in TCR γδ antigen presentation has been further 
confirmed by experiments with MRP5 specific shRNA interference. Cell lines with 
knock down MRP5 have much lower capacity to stimulate TCR γδ cells with 
endogenous and exogenous antigens. However, the decrease in presentation of 
exogenous IPP, when both specific MRP5 inhibitors and specific shRNA 
interference were used, is much smaller as compared with endogenous ligands. 
Therefore, it is likely that our second hypothesis is more accurate. If this is the 
case, then MRP5 would be involved in the presentation of the internalized pool of 
IPP. 
Up to date the physiological function of MRP5 is not clear. It was 
described as transporter for cyclic nucleotides, especially cGMP and was 
suggested that MRP5 removes cGMP from the cytosol during signal transduction 
(Jedlitschky et al., 2000). It is possible that IPP and other prenylated metabolites 
generated in the mevalonate pathway mimic cGMP. Therefore, the role of MRP5 
would be to recognize these substrates and facilitate their removal when they 
accumulate in the cytosol. It is unlikely that MRP5 behaves as an antigen-
presenting molecule for the TCR γδ cells because the predicted extracellular 
MRP5 domains (Persson and Argos, 1994; Belinsky et al., 1998) are too small. 
We therefore, prefer the hypothesis that independent antigen-presenting 
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molecule interacts with TCR γδ. MRP5 may participate in antigen presentation to 
TCR γδ cells by transporting the mevalonate metabolites from the cytoplasm, 
where the metabolites are synthetised. MRP5 protein is localized on the cell 
membrane (McAleer et al., 1999) and perhaps in small amounts intracellularly 
(Wijnholds et al., 1997). These localizations might mediate two different 
mechanisms of action. In the first case, MRP5 may transport mevalonate 
metabolites outside the cell where they finally interact with antigen-presenting 
molecules. A second possibility is that MRP5 facilitates traffic of stimulatory 
metabolites from cytosol inside other compartments, i.e. ER. After transport in 
this compartment, metabolites could bind to the antigen-presenting molecules, 
form a complex and then be transported to the cell surface. This second 
mechanism of action would resemble that of ATP-dependent trasporters 
associated with antigen processing (TAP) involved in peptide traffic from cytosol 
into ER (Neefjes et al., 1993; Momburg et al., 1994). Interestingly, TAP 
molecules are part of complex protein multimers composed of several proteins 
which facilitate the assembly of MHC class I proteins and also provide transport 
and loading of peptides on these presenting molecules (Cresswell et al., 1999). 
At present it is not clear whether MRP5 constitutes multi-subunit complexes with 
other proteins. Interestingly, other transporters are associated with a second 
protein and form complexes which are localized on the cell surface. This is the 
case of MCT4- and MCT1 which form dimers with CD147 on the cell surface 
(Kirk et al., 2000). 
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Taken together our data show that MRP5 is involved in the presentation of 
TCR γδ stimulatory ligand generated in the mevalonate pathway. MRP5 is most 
likely participates in transfer of these phosphorylated ligands from the cytoplasm, 
where they are synthesized, to the cell surface where they are presented to the 
TCR γδ cells.  
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Part  4 
 
Thymic development of TCR Vγ9-Vδ2 cells  
 
Studies in mice have shown that there are several differences between 
human and mouse TCR γδ cells, mainly concerning their tissue distribution and 
antigen recognition. In particular, mice lack TCR genes homologous to the 
human Vγ9 and Vδ2 genes and therefore TCR Vγ9-Vδ2 cells, which represent the 
main population of TCR γδ cells in human peripheral blood, are absent in mice. 
The finding that TCR Vγ9-Vδ2 cells are restricted only to primates (Porcelli et al., 
1991; Haas et al., 1993) has hampered the studies on the development of these 
cells as well as their relative importance in vivo. Therefore, we created a 
transgenic (Tg) mouse model in which mouse T cells express a TCR made by a 
human Vγ9-Vδ2 heterodimer. 
In these studies we investigated which are the requirements for thymic 
maturation and colonization of peripheral lymphoid organs of this unique 
population of TCR γδ cells. 
 
Results 
 
Localization of Tg T cell in lymphoid organs 
The expression of transgenic (Tg) human TCR chains on T lymphocytes 
from single TCR Vγ9-JP-Cγ1 (TCR γ) Tg or TCR Vδ2-Dδ3-Jδ1-Cδ (TCR δ) Tg 
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mice as well as from double TCR γδ Tg mice were analyzed by using monoclonal 
antibodies (mAbs) specific for the human TCR Vγ9 or Vδ2 chains. Analysis of the 
thymocytes from single Tg animals showed that the Tg TCR chains were not 
expressed at the cell surface (Figure 44), indicating that human TCR chains were 
not pairing with any of the endogenous mouse TCR chains. However, high 
expression of human TCR Vγ9 and TCR Vδ2 chains were detected on cell 
surface of double Tg animals, thus showing that the transgenic TCR chains could 
be expressed, pair to each other and assemble with the mouse CD3 complex at 
the surface of mouse cells.  
 
Figure 44. Expression of Tg TCR Vγ9-Vδ2. 
TCR γδ analysis on the thymocytes isolates from single TCR γ, single TCR δ and double 
TCR γδ Tg animals and the WT control. Plots show double staining on total vital 
thymocytes using anti-TCR Vγ9 (Y axis) and anti-TCR Vδ2 (X axis) mAbs. 
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To have a clearer picture of the various cellular populations present in 
these animals, TCR γδ double Tg mice were further bred to recombination 
activating gene 2-deficient (Rag2 KO) mice, which lack endogenous B and T 
lymphocytes due to the impairment of V (D) J recombination (Shinkai et al., 
1992). 
High levels of human TCR γδ expression were found in the thymus of TCR γδ 
Rag-2-deficient Tg mice (Figure 45A), where approximately 65 ± 5% of cells 
were positive for the Tg TCR. The average cellularity of the Tg thymus was 6 x 
107 cells (Figure 45B) thus in Tg animals a total of about 39 ± 3 x 106 cells/per 
thymus expressed the Tg TCR. 
 
 
 
Figure 45. Tg TCR expression in the thymus. 
(A) Surface expression of mouse CD3 and TCR Vγ9 chain on the total thymus of TCR γδ 
Rag-2 KO mice and non Tg littermate control.  
(B) Total number of cells obtained from thymi of Tg TCR γδ Rag-2 KO mice (n=11) and 
non Tg littermates (n=7). 
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When we analyzed peripheral lymphoid organs, we found that, in the spleen 
(Figure 46) and in the lymph nodes (data not shown), only 0.1-0.9% cells bearing 
human TCR γδ were detected (the average of Tg T cells was 1.4 x 104/per 
spleen). 
 
 
 
Figure 46. Surface expression of mouse CD3 and TCR Vγ9 chain on splenocytes. 
Analyzed cells were gated as Mac-1 and B220 negative from TCR γδ Rag-2 KO and non 
Tg control mice. 
 
 
Tg thymocytes have a semi-mature phenotype 
Impairment in the colonization of peripheral lymphoid organs prompted us 
to investigate whether Tg thymocytes were arrested during their development. 
Thymocytes from Rag-2-deficient TCR γδ Tg mice were stained with mAbs 
specific for surface markers characteristic of thymocyte differentiation. While Tg 
animals have similar percentages of thymocytes with DP phenotype, as 
compared to non Tg littermates, they have slightly increased numbers of DN 
cells, compensated by a decrease in the single CD4 and single CD8 positive 
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populations (Figure 47A). Within the thymus approximately 3% of the cells 
express high levels of CD62L (Figure 47B), a marker characteristic of mature 
thymocytes, but the population of CD62Lint cells which co-expresses CD69, the 
population of cells that undergoes positive or negative selections (Swat et al., 
1993; Brandle et al., 1994), is absent in Tg animals (Figure 47B). Thymocytes 
were further analyzed for the expression of CD24 (heat stable antigen, HSA), a 
marker which is gradually lost during the maturation process (Lucas et al., 1993). 
We observed that Tg TCR γδ thymocytes do not downmodulate CD24 (Figure 
47C), thus suggesting a block in thymocytes maturation. Moreover, DN Tg 
thymocytes do not acquire high levels of CD5, a negative regulator of TCR 
signaling (Figure 47D) which is upregulated after the TCR engagement 
(Tarakhovsky et al., 1995; Azzam et al., 1998). These findings show that Tg 
thymocytes express a pattern of surface molecules characteristic of only partially 
mature thymocytes (CD62Lhi, CD24hi, CD5lo) which depicts a maturation arrest 
and is accompanied by lack of egression from the thymus. 
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Figure 47. Analysis of transgenic thymocytes maturation stage as compared to non Tg 
cells.  
(A) The expression of CD4 and CD8 on total thymocytes. Numbers represent 
percentage of cells in each quadrant.  
(B) CD62L versus CD69 cell surface analysis on thymocytes. Numbers represent 
percentages of cells in each gated region.  
(C) CD24 expression analyzed versus CD4 and CD8. Numbers represent percentage of 
cells in each quadrant. 
(D) CD5 expression analyzed versus CD4 and CD8. Numbers represent percentage of 
cells in each quadrant. 
 
 
Tg TCR is functional and induces T cell activation in vitro 
We next investigated the possible reasons why the Tg TCR could not be 
appropriately stimulated in vivo. Firstly, to check whether the CD3-Tg TCR γδ 
complex was functional, we performed activation assays. Freshly isolated 
thymocytes were stimulated in vitro with the anti-TCR Vγ9 mAb (B3) specific for 
the human TCR Vγ9 region, with irrelevant mAb or with concanavalin A (Con A) 
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mitogen. This stimulation induced a strong Tg TCR γδ cells activation as 
demonstrated by upregulation of CD5 (Muller et al., 1997), and CD69 (Testi et 
al., 1989; Swat et al., 1993), comparable with that obtained with Con A (Figure 
48). As control, the same treatment of thymocytes from non Tg littermates did not 
induce any upregulation of these activation markers. Thus, the TCR Vγ9-Vδ2 
heterodimer expressed by Tg thymocytes is functional and after triggering 
induces T cell activation. 
 
 
 
Figure 48. Tg thymocytes respond to an in vitro stimulation with anti-TCR Vγ9 mAb. 
Two color analysis of CD5 and CD69 expression after treatment with indicated stimuli. 
Numbers in upper left quadrant represent percentage of cells which were activated. 
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We further investigated whether Tg T cells were able to respond to the 
stimuli that activate human TCR Vγ9-Vδ2 cells. Various cell types of human or 
mouse origin, were treated with zoledronate (ZOL) and were used as APC. The 
stimulation of Tg T cells was evaluated by checking the expression of CD5 and 
CD69 activation markers. Tg thymocytes were activated by human DC and 
human thymic epithelial cells (TEC) but not by human thymocytes (Figure 49).  
 
 
 
Figure 49. Human APC activate TRC γδ transgenic thymocytes in vitro. 
Two color analysis of CD5 and CD69 expression on Tg thymocytes stimulated with ZOL-
treated APC (DC, TEC and thymocytes). 
 
Several other established tumor cell lines as well as freshly isolated cells 
of both human and mouse origin were also tested. Since only cells of human and 
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not of mouse origin stimulated Tg TCR Vγ9-Vδ2 cells (Table 8), we concluded 
that the lack of proper stimulation in vivo in the mouse was the reason why 
thymocytes do not fully mature and are unable to colonize peripheral lymphoid 
organs. 
 
Responder cells: Human TCR γδ 
clone 
Tg TCR γδ 
thymocytes 
Cell line origin no Ag ZOL no Ag ZOL 
A375 human - + - + 
A431 human - + - - 
Daudi human + + + + 
Jurkat human - + - - 
MOLT-4 human - + - - 
Raji human - + - - 
YMB-1 human + + - - 
THP1 human - + - - 
DC human - + - + 
thymocytes human - - - - 
TEC human - + - + 
DC mouse - - - - 
thymocytes mouse - - - - 
J558 mouse - - - - 
 
Table 8. List of human and mouse APC tested in activation assays using either human 
TCR Vγ9-Vδ2 cell clone or Tg TCR Vγ9-Vδ2 thymocytes as responder cells. 
In case of human TCR γδ clone the response was measured by IFNγ or TNFα release 
(+, statistically significant cytokine release; -, no cytokine release). In case of mouse 
thymocytes expressing human TCR γδ, activation was measured by analysis of CD5 and 
CD69 expression on the cell surface (+, upregulation of both markers as compared to 
control; - ,no change in expression as compared to the control). 
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DN TCR γδ thymocytes proliferate upon in vitro TCR stimulation  
Further analysis of Tg thymocytes showed that upon in vitro stimulation 
they acquire CD4 CD8 DN phenotype (Figure 50). Accumulation of DN cells 
gradually increases with the time of stimulation. Surprisingly we also observed 
increased number of either CD4 SP or CD8 SP cells when we stimulated with 
anti TCR Vγ9 mAb or Daudi cells, respectively. 
 
 
Figure 50. Enrichment of DN Tg thymocytes upon in vitro stimulation. 
Analysis of CD4 and CD8 expression after 24h or 72 h treatment with indicated stimuli. 
Numbers in each quadrant represent percentage of cells. 
 
The observed accumulation of DN Tg thymocytes after in vitro stimulation 
is most likely the result of their proliferation. In order to confirm this hypothesis 
we checked the capacity of DP and DN thymocytes to proliferate when 
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stimulated with anti-TCR Vγ9 mAb (Figure 51). We found that only DN 
thymocytes upon specific TCR stimulation were able to proliferate. 
 
 
 
Figure 51. DN Tg thymocytes proliferate upon TCR stimulation.  
Analysis of CFSE intensity in DN or DP sorted thymocytes treated for four days with anti-
TCR Vγ9 mAb (bold line) or irrelevant mAb (thin line). 
 
 
Triggering of Tg TCR in vivo induces maturation of Tg thymocytes 
In order to bypass the observed maturation arrest and give a stimulus to 
these cells, we triggered the Tg TCR in vivo. Tg mice were injected intra-
thymically (i.t.) with the anti-TCR Vγ9 mAb which was successfully used in the 
previous in vitro experiments. Already one week after injection, thymic 
accumulation of DN thymocytes was observed (Figure 52A). The number of DN 
cells in the thymus of treated animals increased approximately five times in 
comparison to the control animals injected with an irrelevant isotype-matched 
mAb. Direct TCR triggering resulted also in upregulation of CD62L and CD69. 
Approximately 23% of cells expressed high levels of CD62L and 6% of 
thymocytes increased their CD69 expression (Figure 52B). Further investigations 
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revealed that Tg thymocytes upon in vivo TCR γδ stimulation downmodulated 
CD24 and upregulated CD5 (Figure 52C).  
 
 
Figure 52. Analysis of thymocytes maturation stage after TCR triggering in vivo. 
(A) CD4 versus CD8 analysis on total vital thymocytes isolated one week after i.t. 
injection of anti-TCR Vγ9 mAb or irrelevant mAb. Numbers in quadrants represent 
percentage of cells.  
(B) CD62L and CD69 surface expression on thymocytes isolated from mice two weeks 
after i.t. injection of indicated antibodies.  
(C) Surface expression of CD5, CD24 and CCR7 in thymocytes isolated one week after 
i.t. of anti-TCR Vγ9 mAb (bold line) or irrelevant mAb (thin line); grey histogram 
represents negative control (staining with an isotype-matched control antibody). The cell 
population analyzed in each panel is indicated above each histogram. 
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Moreover the levels of CC-chemokine receptor 7 (CCR7), whose 
expression is important for the cortico-medullary migration of positively selected 
thymocytes (Ueno et al., 2004) as well as for the exit from the thymus (Ueno et 
al., 2002), was increased following TCR triggering (Figure 53A). In order to test 
the functionality of CCR7 an in vitro chemotaxis assay was performed. Cells 
isolated from the thymi, after induction of T cell maturation, were specifically 
migrating towards secondary lymphoid-tissue chemokine (SLC), a selective 
CCR7 ligand (Figure 53B). As consequence of CCR7 upregulation the migration 
of thymocytes was enhanced, after induction of T cell maturation. 
Taken together these results suggest that this Tg population needs a 
proper stimulation in the thymus for its normal development.  
 
 
 
Figure 53. Functional analysis of CCR7. 
(A and B) Migration of thymocytes isolated one week after i.t. injection of anti-TCR Vγ9 
mAb () or irrelevant mAb () induced by the chemokine SLC, a selective CCR7 
ligand. (A) Dose dependent migration of thymocytes from two representative animals. 
(B) Thymocytes migration in the presence or absence of the optimal dose (10 nM) of 
SLC is showed for several animals. Cell count was performed in 5 high-power fields 
(5HPF). 
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Upon TCR triggering TCR γδ T cells exit the thymus and colonize peripheral 
lymphoid organs 
We also found that triggering of Tg TCR in vivo induces T cell colonization 
of peripheral lymphoid organs. Seven days post intrathymic injection of anti-TCR 
γδ mAb, Tg T cells were detected in the spleen (Figure 54A) and in the lymph 
nodes (data not shown). After the TCR triggering the percentage of Tg T cells 
was increased up to 6-10% in anti-TCR Vγ9 mAb injected animals compared to 
control mAb-injected animals where Tg T cells were 0.1-0.9%. This results in an 
increase of total number of Tg T cells from an average 0.14x105 to 2.7x105 cells 
per spleen (Figure 54B). Moreover after the egression from the thymus Tg T cells 
persist for a long time in the periphery as demonstrated by staining after 6 
months post injection, which showed amounts of TCR Tg cells similar to the one 
observed after 1-2 weeks (data not shown). 
 
 
 
Figure 54. Analysis of Tg T cells in the periphery. 
(A) Surface expression of CD3 and TCR Vγ9 chain on the Mac-1 negative cells from 
spleen. Cells were obtained from mice 2 weeks after i.t. injection of anti-TCR Vγ9 mAb or 
an irrelevant mAb.  
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(B) Total number of Tg T cells was calculated per each analyzed spleen of mice injected 
i.t. with either irrelevant mAb (n=8) or with anti-TCR Vγ9 mAb (n=8). Horizontal lines 
represent average number of cell in each group. 
 
The vast majority of Tg T cells that colonize peripheral lymphoid organs is 
DN, expresses CD5 and has non activated CD25- CD69low phenotype (Figure 
55). 
 
 
 
Figure 55. Phenotypic analysis of Tg T cells in the spleen. 
Surface expression of CD4/CD8, CD5, CD25, CD69 and TCR Vγ9 two weeks after i.t. 
injection of anti-TCR Vγ9 mAb. Mac-1 positive cells were excluded from the analysis. 
 
The functionality of the cells that colonize peripheral lymphoid organs was 
determined in an in vitro stimulation assay. Peripheral TCR γδ cells were 
activated in the presence of specific anti-TCR γδ mAb as well as in the presence 
of Daudi cells. Activated T cells upregulated CD25 and CD69 markers (Figure 
56A) and also released IFNγ (Figure 56B). These data show that cells which 
colonize the periphery are functional. 
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Figure 56. Tg splenocytes are functional in vitro. 
(A) Splenocytes from mice injected i.t. with anti-TCR Vγ9 mAb were activated with 
indicated stimuli for 24 h and analyzed for expression of CD25 and CD69 activation 
markers. Mac-1 and propidium iodide positive cells were excluded.  
(B) Splenocytes from mice injected i.t. with anti-TCR Vγ9 mAb were activated with 
indicated stimuli for 48 h and mean release of IFNγ ± SD was measured by ELISA. 
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Discussion 
 
The mechanisms governing the development of human TCR γδ cells 
remain largely unknown. The TCR γδ cells development has been mainly studied 
using two mouse TCR γδ Tg models, G8 and KN6. Tg TCR γδ cells in G8 and 
KN6 mouse models carry the rearranged TCR γδ reactive to the MHC class Ib 
T22 molecule (Bluestone et al., 1988; Bonneville et al., 1989; Ito et al., 1990). So 
far it is not clear whether the selection process of these TCR γδ cells requires 
ligand engagement since contradictory results have been published (Wells et al., 
1991; Pereira et al., 1992; Schweighoffer and Fowlkes, 1996; Haks et al., 2005). 
More recent reports provide evidence for ligand-mediated positive selection of 
murine DETC population (Xiong et al., 2004; Lewis et al., 2006).  
In order to study TCR Vγ9-Vδ2 cells in vivo we have generated a 
transgenic mouse model in which human TCR γδ is expressed on mouse T cells. 
Tg TCR was cloned under the control of human CD2 promoter that assured early 
expression of transgene during ontogeny (Duplay et al., 1989; Sen et al., 1989; 
Yagita et al., 1989). Cells expressing the human Tg TCR are very abundant in 
the thymus of Tg mice and they represent the only T cell population present in 
the thymus of Tg mice with Rag-2-deficient background. However, in the 
peripheral lymphoid organs only few cells bearing Tg TCR are present.  
The unusual tissue distribution of Tg T cells could be the result of impaired 
thymic maturation and/or selection. In the thymi of Tg mice we observed only a 
small increase in the percentage of DN cells (up to 10%), together with a reduced 
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number of CD4 SP and CD8 SP cells, as compared to non Tg littermates. This is 
in contrast with other Tg models namely the Tg G8 TCR γδ mice and Tg Vγ6-Vδ1 
TCR γδ  mice in which, DN cells reach approximately 50% of total thymocytes 
(Livak et al., 1997; Hayes et al., 2005). The DP cell compartment was 
comparable to the one observed in non Tg littermates. The presence of DP 
thymocytes in Tg mice is not completely surprising since also in the thymus of 
TCR β -/- mice, where TCR αβ development is arrested, DP cells are present in 
variable numbers (Mombaerts et al., 1993; Passoni et al., 1997). However, the 
DP cells in TCR β -/- mice derive from TCR γδ-expressing progenitor cells but are 
committed to the αβ T cell linage (Kang et al., 1998).  
According to the signal-strength model, in which strong TCR signals promote 
γδ lineage development while weak TCR signals in synergy with Notch signaling 
promote αβ T cell differentiation through DP intermediates (Hayes et al., 2003; 
Haks et al., 2005; Hayes et al., 2005; Garbe and von Boehmer, 2007; Hayday 
and Pennington, 2007). The acquisition of DP phenotype might result from 
impaired stimulation of the Tg TCR γδ. This is also in agreement with the findings 
in Tg KN6 TCR γδ mice in which blocking of the TCR engagement is followed by 
expression of DP phenotype in 90% of thymocytes (Haks et al., 2005).  
Our studies revealed that Tg thymocytes express a pattern of molecules 
characteristic for partially mature thymocytes (CD62Lhi, CD24hi, CD5lo, CCR7-). 
TCRhi DN cells express high levels of CD62L, a marker characteristic of mature 
thymocytes, whereas the CD24 molecule, which is low in mature cells, is not 
downmodulated. In Tg KN6 TCR γδ mice the absence of specific TCR γδ ligand 
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skewed DN thymocytes towards immature CD24hi phenotype while the presence 
of the specific ligand lead to CD24 downmodulation and maturation of TCR γδ 
DN thymocytes (Haks et al., 2005). Additionally we found that, the expression 
CD5, which is upregulated after pre-TCR and TCR engagement (Azzam et al., 
1998), is maintained at low levels on Tg TCR Vγ9-Vδ2 thymocytes.  
During maturation processes T cells upregulate transiently CD69 very 
early after TCR triggering and decline the expression of this surface marker 
shortly after stimuli withdrawal (Testi et al., 1989). In the thymus DP thymocytes 
that are undergoing selection also transiently express CD69 (Swat et al., 1993; 
Brandle et al., 1994) and after the selection they lose the CD69 expression and 
gain expression of the peripheral homing marker CD62L (Gabor et al., 1997). 
Therefore, the absence in Tg TCR Vγ9-Vδ2 mice of cells expressing CD69 in 
another piece of evidence indicating that Tg thymocytes abort their maturation 
process. 
Importantly, Tg thymocytes are able to respond in vitro to various stimuli 
capable of activating human TCR Vγ9-Vδ2 cells in a specific manner. Both anti-
TCR Vγ9 mAb and human APC presenting endogenous antigens were able to 
activate Tg thymocytes indicating that the Tg human TCR associated with mouse 
CD3 complex is functional. Additional analysis of CD4 and CD8 expression 
showed that activated in vitro DN, but not DP, Tg thymocytes are able to 
proliferate. Thus DN Tg thymocytes in terms of phenotype and functionality 
reflect human TCR Vγ9-Vδ2. 
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Taken together these findings suggest that Tg TCR γδ thymocytes in vivo 
do not receive an appropriate TCR stimulation and therefore their thymic 
development is arrested. This is supported by our finding that shortly after in vivo 
TCR stimulation a significant change in the phenotype of Tg T cells is observed 
as compared with controls. Firstly, there was approximately five fold increase in 
the percentage of DN cells meaning that potentially there are more cells that can 
mature into TCR γδ cells. We also observed an increased percentage (from 3% 
to 23%) of cell expressing high levels of CD62L and appearance of CD69 
positive cells. Moreover, the same DN cells which express high levels of Tg TCR 
and CD62L, also dowmodulated CD24 expression and upregulated CD5. Finally 
triggered Tg thymocytes upregulataed functional CCR7. This chemokine receptor 
is expressed in response to TCR engagement and is involved in the emigration 
of newly generated mature thymocytes to the peripheral lymphoid organs (Ueno 
et al., 2002). 
 The direct in vivo triggering of Tg TCR γδ induced change from immature 
(CD62Lhi, CD24hi, CD5lo, CCR7-) to mature (CD62Lhi, CD24lo, CD5hi, CCR7+) 
phenotype of Tg thymocytes, which become able of homing to peripheral 
lymphoid organs. The T cells that colonize the spleen have quiescent phenotype 
(CD25lo CD69lo) and respond in vitro to human TCR γδ stimuli. Moreover, Tg T 
cells persist at least six months (data not shown) in the spleen after the i.t. 
injection of anti-TCR Vγ9 mAb despite the absence of stimulation. 
In our studies we generated a mouse model in which human TCR Vγ9-Vδ2 
cells are present in the thymus but do not exit to the periphery. We have shown 
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that inefficient maturation resulting in the thymic arrest of Tg thymocytes occurs 
due to the lack of appropriate stimulation. By providing specific TCR γδ 
stimulation, maturation and egression of Tg thymocytes was induced. However, 
we cannot conclude whether TCR signaling promotes proper γδ linage choice or 
drives positive selection of Tg TCR γδ cell or both. Importantly, results obtained in 
in vitro stimulation assays might suggest involvement of human DC and/or thymic 
epithelial cells, but not thymocytes, in these processes.
Conclusions 
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Conclusions 
 
This work focuses on the mechanisms responsible for TCR Vγ9-Vδ2 cells 
activation and mechanisms required for the thymic maturation of TCR Vγ9-Vδ2 
cells.  
We have demonstrated that in tumor cells and bacteria infected cells 
alterations in the mevalonate pathway result in activation of TCR Vγ9-Vδ2 cells. 
Therefore, mevalonate dysregulation may serve as a novel type of danger signal 
(Seong and Matzinger, 2004) alerting the immune system of primates. 
Metabolites generated in mevalonate pathway are necessary for sterol synthesis, 
cell growth and membrane integrity (Edwards and Ericsson, 1999). As the 
mevalonate pathway is ubiquitous because it is essential to cell survival, 
mevalonate-deficient cells cannot be generated by selection-induced 
mechanisms. This makes detection of cells with mevalonate pathway alterations 
an optimal system for surveying the metabolic integrity of cells that may be 
altered, either upon tumor transformation or infection. This alert system is unique 
to primates, the only species so far known to have a population of T cells 
reacting to phosphorylated mevalonate metabolites. Although a selective 
advantage of this immune response remains obscure, it is tempting to speculate 
that it is an important protective mechanism during the initial phases of infection 
when antigen specific TCR αβ cells have not been recruited and expanded (De 
Libero, 1997). Therefore, this mechanism should not be inhibited and might be 
exploited for novel immunotherapy. An important consequence of these findings 
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is that the use of drugs that efficiently inhibit cholesterol synthesis by blocking 
HMGR enzymatic activity (Grundy, 1988; Greenwood et al., 2006) deserves 
careful evaluation in patients with infections  
Up to date mechanisms of cellular trafficking and loading, on the putative 
antigen-presenting molecule, of TCR γδ stimulatory ligands has not been 
described. 
Here we demonstrated that MRP5, an ATP-dependent transporter, participates in 
TCR γδ activation process by transporting mevalonate metabolites. Since MRP5 
is known to transport cyclic nucleotides, it could contribute to the clinical 
resistance to nucleoside and nucleotide analogues which are used in anticancer 
and antiviral therapy (Kruh et al., 2001; Adachi et al., 2002). Therefore, targeting 
MRP5 has to be carefully planed since it might hamper the recognition of tumors 
by TCR Vγ9-Vδ2 cells.  
Our results obtained with TCR γδ Tg mice show that the lack of unique 
restriction element in the mouse thymus results in maturation arrest of Tg TCR 
Vγ9-Vδ2 cells. We have shown that when the proper TCR γδ stimulation is 
provided, Tg T cells mature and colonize peripheral lymphoid organs. This 
suggests that TCR Vγ9-Vδ2 cells for the proper thymic development require 
selection process that might be of similar complexities as those required for the 
positive selection TCR αβ cells.
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Materials and Methods 
 
Bacteria 
The following bacteria were used in infection experiments: E. coli 
DH5α and S. aureus Newman. Bacterial cultures in the logarithmic phase were 
obtained by growing E. coli in LB broth (Difco) and S. aureus in TSB broth (Difco) 
at 37°C. Series of 1/10 dilution was prepared and b acteria cell number was 
determined by CFU count after overnight cultures on LB-agar or MH-agar (Difco) 
plates. 
 
Cell culture reagents 
RPMI 1640 medium (BioWhittaker) was supplemented with 1 mM sodium-
pyruvate (Gibco), 50 µM non-essential amino acid (Gibco), 2 mM UltraGlutamine 
II solution (Gibco) and 100 µg/ml Kanamycin (Gibco) and used as base cell 
culture medium. Base medium was supplemented with 10% fetal calf serum 
(FCS, BioWhittaker, Europe) for tumor cell line cultures or with 5% human serum 
(HS, from healthy, blood group AB+ donors, Blutspendezentrum Basel) and 100 
U/ml human recombinant IL-2 for T cell clone cultures. For mouse cell culture the 
D-MEM medium (Gibco) was used to prepare the base medium. 
All the cell culture media were filtered through Stericup GP Express PLUS 0.22 
µM membrane filters (Millipore). 
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Cells 
The following cell lines were used: A-431, an epidermoid cancer; Daudi, a 
Burkitt’s lymphoma; THP-1, a monocytic leukaemia; CEM 1.3, a T cell 
lymphoma; HeLa, a cervix epithelial carcinoma; Colo-201, a coloncarcinoma line; 
HEP-G2, a hepatocarcinoma line, K562 an erythroleukemia line, Raji Burkitt’s 
lymphoma, RJ 2.2.5 MHC class II-deficient mutant of Raji and J558, a mouse 
myeloma cell line all obtained from American Type Culture Collection (ATCC). 
YMB-1, HMC-1-8, and MRK-nu-1 mammary carcinomas were obtained from 
Health Science Research Resources Bank, Osaka, Japan. Primary human lung 
fibroblasts were obtained from M. Bihl; A-375 cells, a malignant melanoma from 
G. Spagnoli, HuH6 hepatoblastoma cell line from E. Köhler; glioblastomas U118 
and BS125.3.2 from A. Merlo (all from University Hospital, Basel, Switzerland); 
astrocytoma A-243 was established from an anaplastic astrocytoma (WHO grade 
III). THP-1 cells transfected with CD1B gene were generated as described 
(Gilleron et al., 2004). 
The following TCR Vγ9-Vδ2 cell clones were used: G2B2, G2B9, G2C19 
obtained as described bellow.  
 
Freezing and thawing of primary cells and cell lines 
Cells were washed once with PBS (BioWhittaker), then resuspended in 
freezing medium containing 90% FCS and 10% dimethylsulfoxide (DMSO, 
Sigma-Aldrich). Samples were stored in liquid nitrogen containing tanks. In order 
to thaw cells, frozen vials were incubated at 37°C until they were thawed and 
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then cells were transferred to 15 ml tubes, slowly buffered with PBS and 
centrifuged. 
 
Preparation of human monocytes and dendritic cells (DCs) 
 Monocytes and monocyte-derived DCs from healthy donors were obtained from 
peripheral blood mononuclear cells (PBMC). PBMC were purified from heparinized 
blood of healthy donors or buffy coat (Blutspendezentrum Basel) using a density 
gradient (Ficoll-Paque, Pharmacia). In brief, blood samples were diluted in PBS (two 
volumes) and slowly applied on a ficoll gradient (3 volumes blood: 1 volume ficoll). 
PBMC were separated by centrifugation at 1000 rpm, room temperature for 20 min 
with slow acceleration and slow breaking rate. Monocytes were sorted from PBMC 
using anti-CD14-labeled magnetic beads (MACS, Miltenyi) according to the product 
protocol. Isolated monocytes were either directly used in antigen presentation assays 
or cultured in 6 well plates (3 ml/well) for 5 days in base medium supplemented with 
10% FCS, GM-CSF (50 ng/ml) and IL-4 (1000 U/ml) at a concentration of 4 x 
105 cells/ml to induce their differentiation into DCs. 
The DC differentiation was checked after 5 days of culture by surface staining 
evaluating expression of antigen-presenting molecules (CD1a, CD1b, MHC class I 
and MHC class II-DR) and costimulation molecules (CD80, CD86). 
 
Expansion of human thymic epithelial cells (TEC) 
 TEC were expanded on a layer of irradiated feeder 3T3-J2 cells. Irradiated 
feeder cells (6000 RAD) 1.8 x 106 were plated in 75 cm2 flasks in base D-MEM/F12 
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medium supplemented with 10% FCS, 5 µg/ml insulin (Sigma), 5 µg/ml human 
transferrin (Behring Diagnostic), 2 nM 3,3’,5 triiodo-L-thyronine sodium salt (T3, 
Sigma-Aldrich), 0.4 µg/ml hydrocortisone (Behring Diagnostic), 100 nM cholera toxin 
(Scharz-Mann), 18 mM adenine (Boehringer Mannheim) ,10 ng/ml epithelial growth 
factor (human recombinant EGF, Chiron Corp.). After 3 h at 37°C TEC (2 x 105/flask) 
were added and grow until confluency. 
 
Generation of human T cell clones 
TCR γδ clones were established from PBMC of healthy donors. Cells 
expressing TCR γδ were sorted using pan anti-δ mAb (δ1) and cloned by limiting 
dilutions in Terasaki plates. Sorted cells were incubated in the presence of 5 x 
105/ml irradiated PBMC (1500 RAD), in 20 µl of base medium supplied with 5% 
HS, 1000 U/ml IL-2 and 1 µg/ml phytohemaglutinin (PHA; Murex, Dartford). After 
10-15 days growing cultures were transferred to 96 well-plates, expanded and 
tested for antigen specificity. 
 
Maintenance of human T cell clones 
Human T cell clones were cultured in base cell culture medium containing 
5% HS and IL-2 at 100 U/ml and expanded by restimulation every 25-35 days. 
Restimulation was performed in the presence of irradiated (1500 RAD) PBMC 
(1:1 ratio) in the same cell culture medium supplied with 1 µg/ml PHA. For 
antigen dependent activation experiments, restimulated T cell clones were used 
12-18 days after restimulation. 
Materials and Methods 
 136 
T cell stimulation assays 
 
Experiments with bisphosphonates 
APC were incubated with different doses of bisphosphonates for 3 h at 
37°C or at 4°C (pulsing) followed by three washes i n PBS before plating (5 x 104 
cells/well) and subsequent addition of T cells (5 x 104 cells/well). In some 
experiments 25 µM mevastatin (MEV, Sigma-Aldrich) was added 2 h before 
bisphosphonates and again after removal of bisphosphonates to maintain a 
constant concentration during incubation with T cells. Farnesol (Sigma-Aldrich) 
and 7-dehydrocholesterol (7-DHC, Sigma-Aldrich) were pulsed on APC for 12 h 
and rinsed out before addition of T cells. Stimulation with IPP (10 µM, Sigma-
Aldrich) and PHA (1 µg/ml) served as positive controls to exclude unspecific or 
toxic effects of the tested drugs. To study the kinetics of activation induced by 
nitrogen-containing bisphosphonate drugs (nBP), Daudi cells were pulsed with 
50 µM pamidronate (PAM), or zoledronate (ZOL), or etidronate (all supplied by 
Novartis) for selected periods (1-18 h), washed three times, and incubated with 
the TCR γδ clone G2B9 for 12 h. T cell activation was estimated by measuring 
cytokine release. 
 
Bacterial infection experiments 
APC were incubated for indicated time periods at 37°C with different MOI 
(range from 0.003 to 3 bacteria: 1 APC), after 3-4 h gentamycin (15 µg/ml, 
Invitrogen) was applied 2 h later TCR γδ cells were added and incubated for 12-
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46 h. In HMGR-blocking experiments, MEV (50 µM) was added 2 h before ZOL 
or bacterial infection and kept in culture during the whole T cell stimulation assay. 
Four different TCR Vγ9-Vδ2 cell clones were used with similar results. All 
experiments illustrated in the figures were carried out with the G2C19 TCR γδ cell 
clone and were repeated at least three times. 
In control experiments the following TCR αβ clones were used: MHC class II-
restricted clone G15A75 specific for a M. tuberculosis peptide antigen (M. 
tuberculosis H37Ra, 50 µg/ml, Difco) and CD1b-restricted clone Z4B27 specific 
for diacylsulphoglycolipids (Ac2SGL, 10 µg/ml), (Gilleron et al., 2004). 
 
Ligand transfer experiment 
The mouse B cell lymphoma cell line M12.4.1 was pulsed with 100 µg/ml 
ZOL of for 2 h at 37°C, washed three times with PBS, and plated (25 x 104 
cells/well) in 96 well plates. DC cells (5 x 104cells/well) and the TCR γδ clone 
G2B9 (5 x 104cells/well) were added. Activation of the TCR γδ clone was 
detected by measuring the TNFα release after 12 h culture. 
 
Experiments with drugs inhibiting transport proteins 
Series of drugs were tested to determine the type of transport protein 
involved in transport of endogenous phosphorylated TCR γδ antigens. In these 
experiments Daudi cells were used as APC. The treatment with ZOL (5 µg/ml) or 
sec-butylamine (SBA, 4 mM, Fluka) was used to induce accumulation of 
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endogenous ligands. Activation with exogenously added IPP or PHA was used to 
control the specificity of the inhibition. Additionally TCR αβ clone CD1a restricted 
and sulfatide specific was used to determined specificity of inhibition to TCR γδ 
cells.The transporter inhibitors were purchased from Sigma-Aldrich accept: PSC-
883 and PKF-274-266 provided by Novartis; methotrexate and MK-571 
purchased from Alexis. 
APC were treaded with ZOL or SBA for 3h, then drugs were applied to the 
culture and 3 h later T cells were added. In parallel the pulsing experiments were 
performed. In case of pulsing experiments APC were treated with ZOL or SBA for 
3 h then drugs were added for additional 6 h. Then APC were washed and T 
cells were added and incubated for 6 h. T cell activation was determined by 
measurement of TNFα release. When toxic effects where occurring by keeping 
the drugs overnight, only the data from the experiments with pulsed drugs were 
considered. A series of concentrations were tested for each drug, according to 
the literature. A positive inhibition of antigen transport was considered only at 
drug concentrations, inhibiting activation by SBA and ZOL, but not exogenous 
IPP, PHA activation, nor activation of the TCR αβ clone.  
Some drugs showed at each concentration some toxic effects together with a 
strong inhibition of activation by ZOL or SBA. In these cases the highest value of 
inhibition detected with IPP, PHA or the TCR αβ clone was subtracted from the 
value of ZOL inhibition. Specific inhibition was expressed as percent of inhibition 
in relation to TCR γδ cell activation in the absence of drug (100% response). 
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Cytokine determination by Enzyme Linked Immunosorbent Assay (ELISA) 
Released cytokines from T cell activation assays were measured by 
ELISA. ELISA plates (Maxisorb, Nunc) were coated with the capture antibodies 
for 12 h at 4°C, dissolved in PBS at a concentratio n from 1-10 µg/ml, containing 
0.02% NaN3 (Fluka). The incubation of the coating antibody was done using 70 
µl of antibody solution per well. After coating, the ELISA plates were washed 
once with washing buffer containing PBS and 0.05% Tween 20 (Fluka) on a plate 
washer (ELX50 autostrip washer, Polygon Science) and wells were blocked with 
200 µl of blocking buffer containing PBS, 0.05% Tween 20 and 1% bovine serum 
albumine (BSA, Sigma-Aldrich) for at least 1 h at room temperature. After 
blocking, plates were washed and incubated for 2 h with 70 µl of sample or the 
standard recombinant cytokines. Then plates were washed three times with 
washing buffer and incubated for at least 1 h with 70 µl of the detection antibody, 
diluted in blocking buffer at 1-5 µg/ml. After incubation plates were washed again 
three times and incubated with 70 µl of Streptavidin-HRP (Zymax Streptavidin-
HRP conjugate, Zymed) diluted in blocking buffer 1:4000. After 1 h incubation, 
plates were washed five times and incubated with 90 µl of the substrate solution 
(fast o-phenylenediamine dihydrochloride tablet, Sigma-Aldrich). The substrate 
incubation was done for 5-10 min then stopped by addition of 10% H2SO4 (50 
µl/well, Fluka). The absorption was read at 490 nm, with an ELISA reader 
(Spectra Max 190, Molecular Devices). The samples were expressed as 
duplicates or triplicates and concentration of the cytokine was calculated with a 
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standard curve made by serial dilutions of the appropriate recombinant cytokine 
(Pharmingen). 
The following coating antibodies were used: MAb1 (BD, Pharmingen) for human 
TNFα; HB 8700 (ATCC) for human IFNγ; 8D48 antibody (BD Biosciences) for 
human IL-4 and JES6-1A12 (BD Biosciences) for mouse IL-2. 
The following revealing biotinylated antibodies were used: MAb11 (BD 
Biosciences) for human TNFα; γ69-2GV for human IFNγ; MP4-25D2 (BD 
Biosciences) for human IL-4 and JES6-5H4 (BD Biosciences) for mouse IL-2. 
 
Recombinant cytokines production 
Human cytokines IL-4, IL-6, IL-2, GM-CSF and mouse GM-CSF were 
obtained by culturing J558 cells transfected with plasmid containing the 
appropriate human cytokine cDNA in base cell culture medium supplemented 
with 10% FCS. Cell-free culture supernatants were harvested from cell cultures 
containing 1-2 x 107 cells/ml. The concentration of hGM-CSF, hIL-4, hIL-6 and 
mGM-CSF were determined by ELISA. The active units of human IL-2 were 
measured using the standard IL-2-dependent cytotoxic T cell line (CTLL-2) 
proliferation assay. 
 
Generation of stable transfectants 
Hamster HMGR cDNA (pRed-227;ATCC), was amplified with the following 
primers: 
5’HamHMG_XhoI_ ATCTCGAGGGACCGAGTGGCTACAATG; 
3’HamHMG_HincII_ATGTCGACAGCTGACTTCTTGGTGCACG; 
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and subcloned (XhoI/ HincII) into pBluescript II KS (Stratagene). The gene was 
tagged at the 3’ end with a sequence for 19 amino-acid long BirA peptide 
(KLGGGLNDIFEAQKIEWHE) and was further subcloned (XhoI/NotI) into 
BCMGSNeo expression vector (Karasuyama et al., 1990).  
pABC11 (McAleer et al., 1999) plasmid construct containing MRP5 fused to GFP 
(N. Matthews Yamanouchi Research Institute, United Kingdom and P.Artursson 
Department of Pharmacy, Uppsala University, Sweden) was used to transfect 
different cell lines. A-375 cells were transfected with 200 ng DNA using Effectene 
(Qiagen) and Daudi cells were tansfected with 10 (g of DNA by electoporation. 
For both cell lines permanent transfectants were selected with 0.8 mg/ml of G418 
(Calbiochem). 
 
Genaration of MRP5 shRNA interference constructs 
PSHAG-1 and pSHAG-Ff1 plasmids (Paddison et al., 2002) containing U6 
promoter only and firefly luciferase gene specific small hairpine RNA (shRNA) 
interference, respectively were kindly provided by G.J. Hannon (Watson School 
of Biological Sicences, Cold Spring Harbor, USA). The following oligonucleotide 
pairs were annealed and inserted into pSHAG-1 plasmid (BseR I/BamH I) in 
order to generate MRP5 sequence specific shRNA interference constructs: 
42_forward_TTCTCTCCCTCACACTTCTATACCCAGGGAAGCTTGCTTGGGTG
TAGAAGTGTGAGGGGGAGAATCATTTTTT; 
42_reverse_GATCAAAAAATGATTCTCCCCCTCACACTTCTACACCCAAGCAA
GCTTCCCTGGGTATAGAAGTGTGAGGGAGAGAACG; 
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1501_forward_GGCGAGTTCTGGATACTGGAGTGGGAGGGAAGCTTGCTTCT
CATTCTAGTATCCAGAACTCGCCCAATTTTTT; 
1501_reverse_GATCAAAAAATTGGGCGAGTTCTGGATACTAGAATGAGAAGC
AAGCTTCCCTCCCACTCCAGTATCCAGAACTCGCCCG; 
2526_forward_CCTGGATGTAGACACCATATACTGACCAGAAGCTTGTGGTTA
GTATGTGGTGTCTGCATCCGGGCTGTTTTTT; 
2526_reverse_GATCAAAAAACAGCCCGGATGCAGACACCACATACTAACCAC
AAGCTTCTGGTCAGTATATGGTGTCTACATCCAGGCG; 
3344_forward_AATCTGCCCGTGCATAAGAACGATCATCGAAGCTTGGGTGGT
CGTTCTTGTGCACGGGCAGGTTCCCTTTTTT; 
3344_reverse_GATCAAAAAAGGCAACCTGCCCGTGCACAAGAACGACCACC
CAAGCTTCGATGATCGTTCTTATGCACGGGCAGATTCG; 
The name of each construct contains the number, which correspomds to the 5’ 
binding position within the MRP5 mRNA sequence. 
Further subcloning (EcoR V/Not I) into the pCMV/Zeo (Invitrogen) expression 
vector was performed. Obtained constructs were used to generate stable 
transfectants as before. 
 
RT-PCR analysis of HMGR  
Total RNA was extracted (RNeasy, Qiagen) from THP-1 cells infected with 
E. coli (MOI=1) for the time points indicated in Figure 29B (Part 2) and from A375 
wt cells and A375 cells transfected with MRP5 shRNA interference constructs 
and control Ff1 construct. Two µg of RNA were used for cDNA synthesis 
(Superscript III, Invitrogen) and PCR was then performed on series of 1:3 cDNA 
dilutions using Taq Polymerase (NEB). The following primers were used: 
HMGR: 5’for_TGGCTGAAACAGATACCCCAAAC; 
3’rev_CACCTCCACCAAGACCTATTGC; 
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β-actin: 5’for_CACAGAGCCTCGCCTTTG; 
3’rev_TGGATAGCAACGTACATG; 
PCR conditions were adjusted according to the sequence of primers and the 
length of generated products. Bands were scanned, HMGR and MRP5 products 
were compared with β-actin level for all time points and dilutions. 
 
Real-time quantitative PCR of MRP4 and MRP5 
MRP4 and MRP5 mRNA expression levels were checked by real-time 
quantitative PCR as described (Pfrunder et al., 2003). Briefly, total RNA was 
isolated from different cell lines (RNeasy, Qiagen) and 1 µg of RNA was used for 
cDNA synthesis (Superscript III, Invitrogen) using random hexamers as primers. 
A total of 25 ng cDNA was used as a template for real-time quantitative PCR. To 
standardize the amount of sample cDNA added to the reaction the calculated 
amount of the gene of interest was compared with the amount of constitutively 
expressed glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene. 
The following primers and probes were used: 
for MRP4: 
Forward_ACCAGGAGGTGAAGCCCAAC; 
Probe_CGCTGCAGGACGCGAACATCTG;  
Reverse_AGGGATTGAGCCACCAGAAGA; 
for MRP5: 
Forward_CTGCAGTACAGCTTGTTGTTAGTGC; 
Probe_CTGACGGAAATCGTGCGGTCTTGG;  
Reverse_TCGGTAATTCAATGCCCAAGTC; 
GAPDH: 
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 Forward_GGTGAAGGTCGGAGTCAACG; 
Probe_CGCCTGGTCACCAGGGCTGC;  
Reverse_ACCATGTAGTTGAGGTCAATGAAGG; 
 
Immunoprecipitation of HMGR 
Daudi or THP-1 cells (5-2 x 107) either untreated or treated with: farnesol 
(50 µM) or 7-DHC (100 µg/ml) for 12 h or infected with bacteria (MOI=1) for 
different time points. Cells from each group were washed three times with PBS, 
counted and lysed on ice in lysis buffer containing 50 mM KH2PO4 (MERK), 150 
mM NaCl, 5 mM EDTA (Sigma-Aldrich), 1% Triton X-100 (Fluka), 5 mM PMSF 
(Axon Lab AG), 10 µg/ml Leupeptin (Sigma-Aldrich), 50 µl Inhibitor mix 
(Boehringer Mannheim) at pH 7.4. Lysates were centrifuged at 15000 rpm for 15 
min at 4°C to remove insoluble material. Supernatan ts were transferred to new 
eppendorf tubes on ice. 
In order to perform an immunoprecipitation lysates were firstly pre-cleared with 
60 µl of protein G-sepharose (50% in lysis buffer, GE-Healthcare Biosciences 
AG) for 1 h on a turning wheel (Bender Hobein Scientific Instruments, Inc.) at 
4°C. After the pre-clearing, lysates from each samp le were incubated with anti-
HMG-CoA reductase rabbit polyclonal antiserum (R. Simoni, Stanford University, 
Palo Alto, CA and J. Roitelman, Sheba Medical Center, Tel Hashomer, Israel) for 
12 h at 4°C under rotation on a turning wheel. Then  60 µl of protein G-sepharose 
were added and incubated for 3 h on the turning wheel, to precipitate the 
antibody. After this step protein G-sepharose was centrifuged as above and 
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subsequently washed 2 times with 1 ml of lysis buffer and 2 times with 1 ml of 
PBS. 
Electrophoresis, transfer and western blotting 
Precipitated antigen was released from the antibody and protein G-
sepharose pellet, by addition of 40 µl of 2x concentrated reducing sample buffer 
containing 60 mM Tris HCl pH 6.8 (Fluka), 30% glycerol (Fluka), 10% sodium 
dodecyl sulfatide (SDS, Sigma-Aldrich), 4 mM Na2EDTA (Fluka), 4% 2-
mercaptoethanol (Sigma-Aldrich) and 0.005% bromophenol blue (Fluka). 
Samples were incubated at 95°C for 5 min. Then the sepharose-residues were 
removed by centrifugation at 14000 rpm for 10 min at room temperature and 
supernatant applied on an electrophoresis gel. 
20 µl from each sample were applied with Hamilton syringes (Hamilton Bonaduz) 
in the slots of a stacking polyacrylamide gel (5% polyacrylamide content, 0.75 
mm thickness), overlaid above a separating acrylamide gel (8.5% polyacrylamide 
content, 0.75 mm thickness) in an electrophoresis aperture (Mini Protean IITM). 
After application of the samples and a molecular weight marker (Rainbow, 
Biorad), the gel electrophoresis aparatus was connected with a power supply 
(Model 1000/500, Biorad) and voltage was applied at 20 Volt during run in the 
stacking gel and 40 Volt during the run in the separating gel. 
Composition of running buffer for electrophoresis (pH 8.8): 3 g of Tris, 14.4 g of 
glycin (Fluka), 1 g of SDS per 1 l; 5% stacking gel: 2.3 ml of Tris (0.5 M in water, 
pH 6.8), 100 µl of SDS (10% in water), 1.5 ml acrylamide (30%, Biorad), 100 µl 
APS (10% in water, Fluka), 10 µl of TEMED (Fluka) and water up to 9 ml; 8.5% 
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separating gel: 2.5 ml of Tris (1.5 M in water, pH 8.8), 100 µl of SDS (10% in 
water), 2.9 ml acrylamide (30%), 50 µl APS (10% in water), 5 µl of TEMED and 
water up to 10 ml. After separation proteins were transferred to a nitrocellulose 
membrane. The separating gel was removed from the apparatus and 
preequilibrated in transfer buffer for 15 – 30 min. Then the gel was attached to a 
nitrocellulose membrane (0.2 µM Hybond-C extra, Amersham) of identical size 
and inserted in a transblot apparatus (Mini protean II, Biorad) supported by filter 
papers (GB 002 Gel-Blotting-Paper, Schleicher & Schuell) and sponges. The 
transfer apparatus was filled with transfer buffer, connected to a power supply 
(Model 1000/500, Biorad) and transferred under constant current conditions (200 
mM) for 4 h at 4°C. Buffer was cooled by ice and stirred with a magnetic stirrer 
during transfer. When transfer was finished, nitrocellulose membrane was 
removed, washed in PBS and immersed in a solution of 5% gelatin (Top Block, 
Juro) dissolved in PBST (PBS, 0.05% Tween 20) at 4°C overnight for blocking. 
Composition of transfer buffer: 3 g of Tris, 14.4 g of glycin, 20 ml of CH3OH 
(Fluka) per 1l. 
After blocking, the membrane was washed three times for 5 min with an excess 
of PBST, then incubated with the mAb against HMGR (A9-biotinylated, ATCC) 
dissolved in PBST, 2.5% gelatin at a concentration of 5 µg/ml for 3 h under 
shaking at room temperature. Then the membrane was again washed three 
times in PBST and incubated with a Streptavidin-HRP (SBA), diluted 1:2500 in 
PBST + 2.5% gelatin for 1 hr. The membrane was washed three times with 
PBST, 2 times with PBS, finally the enhanced chemoluminescence reaction 
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(ECL-reaction) was performed. The ECL-reaction was done with a supersignal kit 
(Pierce). After 5 min incubation the excess of liquid was removed, membrane 
was wrapped and exposed to X-ray film (Biomax MR, Kodak) for various times. 
The film was developed using X-ray film developer (Curix 60, AGFA). 
 
HMGR phosphorylation studies 
A-375 HMGR-transfected cells (107/group) were lysed as before with 
addition of phosphatase inhibitor cocktail 1 (Sigma-Aldrich). Immunoprecipitation 
was performed as described above using the anti-BirA tag mAb Bir1.4 (Nowbakht 
et al., 2005). Blots were incubated with anti-phosphoserine mAb (7F12, Alexis), 
HRP-conjugated goat anti-mouse IgG1 (SBA) and chemiluminescence substrate 
(Supersignal,Pierce). As a control, membranes were stripped using the 
RestoreTM Western Blot Stripping Buffer (Pierce) and total HMGR Western blot 
was performed as described previously. In order to calculate % of HMGR 
phosphorylation, bands were scanned and the total HMGR protein levels were 
compared with corresponding levels of phosphorylated HMGR (time 0 was 
considered as 100%). 
 
PP2A activity assay 
A-375 HMGR-transfected cells were lysed (25 mM Tris HCl, pH 7.5, 2 mM EDTA, 
10 mM 2-mercaptoethanol and protease inhibitors) and PP2A activity was 
determined using the Serine/Threonine Phosphatase Assay System (Promega) 
according to the manufacturer’s protocol. 
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Calcium flux measurement 
Daudi cells were labeled with CFSE (0.5 µM, Molecular Probes) 2 days before 
the assay. In the control samples a low dose of ZOL (5 µg/ml) was added to 
Daudi cells 1 day before the assay to induce accumulation of TCR γδ cells 
ligands. Cells were washed and incubated with phosphatase inhibitor: okadaic 
acid (OA, 100 nM, Alexis) or calyculin A (CA, 10 nM, Alexis) for 4 h. In control 
samples ZOL (50 µg/ml) was added together with inhibitors. Cells were washed 
and resuspended in 5% FCS RPMI 1640 without phenol red (fluxing medium) at 
6 x 106/ml. TCR γδ cells were labeled with Indo-1 (Sigma-Aldrich) dye according 
to standard protocol and resuspended in fluxing medium at 6 x 106/ml. APC and 
T cells were mixed (1:1 ratio) and immediately analyzed with FACS VantageTM 
(Becton Dickinson), to detect the base line. After 30 seconds cells were removed 
and centrifuged for 10 seconds (600 g) in order to facilitate formation of cell 
conjugates and reapplied to the cytometer. Acquisition was carried for 5 min. The 
ratio of fluorescence emission of Indo-1 Ca2+-bound (405 nm) to unbound (485 
nm) was plotted against time. Samples were analyzed using FlowJO software 
(Tree Star, Inc.) after gating on doublets containing Daudi cells (CFSE+) and T 
cells (Indo-1+). 
 
HMGR activity assay 
The assay is a slightly modified derivation of the method previously 
described (Park et al., 2001; Gerber et al., 2004). Cells (107/group) were lysed by 
seven freeze and thaw cycles using liquid nitrogen and a 37°C water bath. 
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Homogenate cell pellets were resuspended in 500 µl of activation buffer 
containing 50 mM K2HPO4, 1 mM EDTA, 5 mM DTT (Fluka) at pH 7.5, and left 
for 20 min at 37°C to activate HMGR. To perform HMGR enzymatic assay, 250 µl 
of reaction buffer (125 mM K2HPO4, 12.5 mM DTT, pH 7.5) were added to 500 µl 
of homogenate. The reaction mix containing 15 mM NADPH (Sigma-Aldrich) and 
0.4 mM HMG-CoA (Sigma-Aldrich) or water with 0.4 mM HMG-CoA were added 
to reach a final volume of 917 µl. The assay was performed at 37°C and stopped 
after 60 min by addition of 83 µl of 37% fuming HCl (Fluka). Homogenates were 
incubated 15 h at room temperature to promote conversion of mevalonate into 
mevalonolactone (MVL) and to precipitate proteins. A calibration curve was 
performed on the homogenates treated with water. All samples were filtered 
through a Sep-Pak® Classic C18 Cartridges (Waters). 
 
LC-MS analysis of HMGR products 
A triple quadrupole TSQ Advantage Max (Finnigan) equipped with an 
electrospray source was coupled to a Rheos 2000 HPLC system (Flux). The 
HPLC separation was achieved on a reverse-phase Nucleosyl C18 column 
(Macherey-Nagel,125 x 2 mm i.d.). Ten µl were injected onto the column and 
eluted with 10% acetonitrile (Rathburn) and 0.1% formic acid (AppliChem) in 
water, at a flow rate of 0.2 ml/min during 10 min. The nitrogen nebulizing 
pressure was 45 psi with a heated capillary temperature at 300°C. The 
electrospray needle was set at 4.0 kV. Single ion monitoring (SIM) mode was 
selected (m/z 131 ± 10) for MVL in the third quadrupole. MVL detected in each 
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sample was quantified by creating a calibration curve by adding increasing 
amounts of MVL (0.1-5 µM) to samples containing cell homogenates with water. 
The concentration of MVL was determined from the SIR (m/z 131 ± 0.2) peak 
area at 2.7 min. 
 
Mevalonate kinase, phosphomevalonate kinase and diphosphomevalonate 
decarboxylase activity assays 
The assays are a slightly modified derivation of the method previously 
described (Biardi et al., 1994; Krisans et al., 1994). Cells were lysed by seven 
freeze and thaw cycles using liquid nitrogen and a 37°C water bath. Homogenate 
cell pellets were resuspended in 100 µl of water and 300 µg of total protein from 
cell lysates were used in the enzymatic reactions. Radioactive precursors (50 
mM, 1.22 x 105 dpm/nmol (RS) [2-14C] mevalonate for MVK activity assay or 50 
mM, 2.87 x 105 dpm/nmol (RS) [2-14C] mevalonate-5-P for PMVK and MVD 
activity assay, GE Healthcare) were added to the reaction mix containing: 15 mM 
CHAPS (Sigma-Aldrich), 0.1 M KPO4 (Fluka), 15 mM ATP (Sigma-Aldrich), 4 mM 
MgCl2 (Fluka), 1 mM DTT, 1 mM EDTA at pH 7.4. Control reactions were 
performed in the absence of ATP. 
Enzymatic reaction was carried out at 37°C and stop ped after 60 min by boiling. 
Samples were separated on a 2 ml AG 1-X8 200-400 mesh formate resin column 
(Biorad) and products were eluted using: 2 N formic acid (for mevalonate 
elution), 4 N formic acid (for phosphomevalonate elution), 0.4 M ammonium 
formate in 4 N formic acid (for diphosphomevalonate elution) or 0.8 M  
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ammonium formate in 4 N formic acid (for IPP elution). Three ml fractions were 
collected for each elution step and each fraction was analyzed on β-counter.  
 
Induction of mevalonate pathway products in cell lysates 
Daudi cells (5 x 108) were lysed on ice in 4 ml detergent free, hypotonic 
lysis buffer containing 50 mM HEPES (BioWhittaker), 5 mM MgCl2, 2 mM MnCl2 
(Merk) at pH7.5. The lysate was centrifuged at 104 g for 1 h, at 4°C on an 
ultracentrifuge (XL-70 K, Beckman-Coulter) using the rotor SW55TI (Beckman-
Coulter), to remove organelles, membranes and insoluble material. Then the cell 
lysate was concentrated 4 times with a 10 kDa cutoff centrifugal filter (ultrafree 
centrifugal filter device, Millipore) on a centrifuge at 6000 rpm, until a volume of 1 
ml was reached. 25 µl of the concentrated lysate was mixed with 75 µl of reaction 
buffer containing mevalonic acid (Anawa), (10 mM KH2PO4, 11 mM KF, 3 mM 
DTT, 7.5 mM MgCl2, 7.5 mM ATP, 0.1 mM MVA (R, S-), 0.4 µCi MVA (R, S) [5-
3H], pH 7.5) and incubated for 60 min at 37°C. React ion was stopped by addition 
of 100 µl methanol (Fluka) and putting on ice for several minutes. The sample 
was clarified from the precipitated proteins by centrifugation at 9000 rpm and 
stored at -20°C. 
Twenty µl of the metabolite mixture were lyophilized in an eppendorf tube, 
resuspended in 45 µl water and treated with 6 units of alkaline phosphatase 
(Boehringer Mannheim) which cleaves organic pyrophosphate-esters. The 
reaction was performed for 3 h at 37°C. To test the  biological activity of this 
supernatant, 25 µl of phosphatase-treated solution were added to 96 well plates, 
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lyophilized and resuspended in culture medium containing 10% FCS. THP-1 cells 
were used as APCs (5 x 104 cells/well) and the TCR γδ clone G2B9 (5 x 104 
cells/well) as responder cells, in a final volume of 200 µl medium per well. After 
12 h, activation was measured by the released of TNFα. Phosphatase-treated 
samples were compared with an equal amount of non-phosphatase treated 
samples. As control for toxicity, the glycolipid sulfatide was treated using the 
same conditions as above and used to activate a sulfatide specific T cell clone. 
 
Separation of the mevalonate metabolites by HPLC 
An aliquot of the filtered metabolite mixture was injected in a HPLC 
system (PU-980 HPLC pump, Jasco) and the organic components were 
separated on a Spherisorb SAX 5µ HPLC column (4.6 mm X 25 cm; VDS 
Optilab) using a gradient of two buffers A and B, composed of 78% 10 mM 
KH2PO4, 20% acetonitrile, 2% tetrahydrofuran (THF, Merk) at pH 4.5 and of 70% 
10 mM KH2PO4, 25% acetonitrile, 5% THF at pH 4.5, respectively. This type of 
separation allowed separation of prenylated phosphorylated metabolites from 
other organic components in the mixture. The gradient formed by these two 
buffers was: 0-2 min 0% B, 2-13.5 min 57% B, 13- 14.5 min 99% B, 14.5-35 min 
99% B. The metabolic products were detected by their radioactivity using a β-
scintillation detector (Radiomatic Flow Scintillation Analyzer, Packard) connected 
with the HPLC system. As scintillation liquid an Ultima Flo M (Packard Instrument 
Co.) was used. In separate HPLC-runs, 3H-IPP (ARC) and 3H-MVA (Anawa 
Radiochemicals) were injected and used as reference to correlate the retention 
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times of radioactive peaks in the metabolite mixture, with the retention time of 
these standard substances. In other separate HPLC-runs, the β-scintillation 
detector was disconnected and instead the separated components were 
collected in sample tubes (Sarstedt) in intervals of 15 seconds, using a fraction 
collector (2211 Superrac, LKB Brommer). The acidic pH of the mobile phase was 
immediately neutralized by adding 20 µl of 2 N KOH (Fluka) in each fraction. 
From each fraction aliquots were transferred in a 96 well plate (5 µl/well), 
lyophilized, resuspended in cell culture medium and used to stimulate the TCR γδ 
clone G2B9 (5 x 104 cells/well) in the presence of THP1 cells as APC (1.5 x 
104/well). After 12 h, activation was determined by measuring released TNFα by 
ELISA assay.  
 
Structural identification of the antigenic fraction by mass-spectroscopy 
The active fraction, identified by activation of TCR γδ cells was desalted 
before mass-spectroscopy. Desalting was done with an anion-exchange DEAE-
sepharose filled in a cartridge (DEAE-sephacel, Pharmacia). The DEAE-
sepharose (250 µl) was fixed with two filters in a cartridge, washed one time with 
10 ml water, subsequently with 10 ml of a TEA-acetate solution (800 mM in 
water) and again with 10 ml of water. The active fraction was centrifuged under 
vacuum in a speedvac centrifuge (DNA 110, Savant) for 2 h, to remove the 
organic solvents THF and acetonitrile. The water/TEA-acetate pretreated 
cartridge was slowly loaded with the active fraction. Subsequently the cartridge 
was flushed with 20 ml of a 50 mM TEA-acetate solution to remove the inorganic 
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phosphate. The stronger bound organic pyrophosphorylated compounds were 
eluted with 800 µl of a 200 mM TEA-acetate solution and separated in this way 
from inorganic phosphate anions originating from the HPLC-buffer. The TEA-
acetate was lyophilized and the solid substance solubilyzed in 10 µl of a 50% 
methanol solution. A few microliters were loaded into a nanospray tip (Protana 
Engineering A/S). The spray was initiated at a voltage of 1100 V. Spectra were 
recorded on a Finnigan TSQ7000 instrument (Finnigan) in negative ion mode set 
to 1 D resolution. 
 
14C-ZOL uptake 
Daudi cells were pulsed with 14C-ZOL (25 µg/ml, corresponding to 700 
nCi/ml, Novartis) for 3 h at 37°C or at 4°C, and wa shed three times with PBS. 
Some experiments included monensin (20 µM, Sigma) and NaN3 (0.05%) during 
the ZOL pulse. After the last wash, 106 Daudi cells from each group were 
resuspended in 1 ml PBS, transferred to scintillation tubes (Pico Pro Vial, 
Packard) and lysed by adding 2 ml of scintillation liquid (IRGA-SAFE PLUS, 
Packard Bioscience BV). Radioactivity was counted with a β-counter (TR 1900, 
Canberra Packard). Triplicate samples were evaluated. 
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Mice 
Generation of human TCR γδ tg mice. Full length human cDNA containing 
TCR Vγ9-JP-Cγ1 (TCR Vγ9) or TCR Vδ2-Dδ3-Jδ1-Cδ (TCR Vδ2) regions, 
obtained by RT-PCR from the previously established TCR γδ clone D1C55, were 
cloned into VA expression vector under control of the human CD2 promoter 
(Zhumabekov et al., 1995).  
Primers used for cloning of human TCRγ and TCRδ genes: 
TCR Vγ9 chain: 5’gammaS2_GGGTCGACTGCGGTGATTTCA; 
3’gammaN_GCATGCGGCCGCCACCGTC; 
TCR Vδ2 chain: 5’deltaS_GGGTCGACGTGGTTGAGAGGC; 
3’deltaN_GCATGCGGCCGCTTCCTCATG; 
Each construct, devoid of vector sequences, was used for microinjection 
into (C57BL/10 x CBA) F2 fertilized oocytes. Mice transgenic for human TCR Vγ9 
(B6;CBA-Tg(CD2-TRGV9/JP/C1)7Dfim) or Vδ2 (B6;CBA-Tg(CD2-
TRDV2/D3/J1/C)15Dfim) chains were obtained and inter-bred in order to 
generate TCR Vγ9-Vδ2 double transgenic animals. TCR γδ transgenic mice 
having RAG-2 deficient background were also obtained by breeding with 
B6.129S6-Rag2tm1FwaN12 (Shinkai et al., 1992). 
MyD88-/- (Adachi et al., 1998) and C57BL/6 mice were maintained and bred in 
the animal facility at our Institute. All animals used for experiments were 
sacrificed at 4 -10 weeks of age. This study was approved by the “Kantonales 
Veterinaeramt Basel-Stadt”. 
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Screening of transgenic mice 
Mice were marked for long time identification and tail biopsy was 
performed according to the rules of “Kantonales Veterinaeramt Basel-Stadt “. Tail 
samples were placed in Eppendorf tube (1.5 ml) and incubated over night at 
56°C in 500 µl of lysis buffer containing 100 mM Tris HCl, 5 mM EDTA, 0.2% 
SDS, 200 mM NaCl, 0.4 mg/ml Proteinase K (Axon Lab). Lysates were 
centrifuged for 10 min at maximal speed and transferred to fresh tubes. DNA was 
precipitated with one volume of isopropanol (Fluka) and recovered using glass 
capillaries. After placing the capillaries for 5 min in 70% ethanol, DNA was dried 
and resuspened in 400 µl of TE (10 mM Tris HCl, 1 mM EDTA, pH 7.5). Obtained 
DNA samples were diluted in TE buffer to reach a concentration of 30 µg/ml and 
1 µl was used for PCR. 
PCR was preformed according to the protocol using Taq Polimerase (NEB). 
Primers used for identification of TCR γδ tg mice:  
for TCR Vγ9 chain and TCR Vδ2 chain as above; 
mRag 2:  5’mRAG2for_TCTAAAGATTCCTGCTACCTCCCAC; 
3’mRAG2rev_TGAAAAGACAGCCCATCCTGAAG; 
neomycin cassette:  5’NEOfor_TGGGCACAACAGACAATCGG;  
3’NEOrev_TGGATACTTTCTCGGCAGGAGC;  
PCR conditions were adjusted according to primer sequences and size of the 
generated products. 
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Intrathymic injections 
Animals were anesthetized by i.p. injection of 30 µg/10 g body weight of 
ketamine (Ketalar, 50 mg/ml, Parke-Davis): xylazine (Xylasol, 20 mg/ml, Graeub) 
mixed 2:1 in sterile 0.9% NaCl solution (Fluka). The upper part of the thoracic 
cavity was opened to expose thymic lobes. Lobes were injected with 40 µg of 
indicated mAb in sterile PBS solution. Mice were administered s.c. with the 
analgesic, 1 µg/10 g body weight Temgesic (Reckitt Benckiser Healthcare, UK). 
Mice were sacrificed between 1 and 3 weeks after injection. 
 
Preparation of mouse lymphoid cells 
The organs of interest were isolated from sacrificed mice under sterile 
conditions and placed in D-MEM (Gibco) medium supplied with 10% FCS, 100 
µg/ml Kanamycin and 10 mM HEPES buffer. Cells were isolated by mashing the 
organs on metal sieves using 2 ml syringe plunges. Isolated cells were 
transferred to 15 ml conical bottom tubes and incubated for 5 min at room 
temperature. Clear suspensions were transferred to new tubes avoiding tissue 
debris. In case of cell preparation from spleen, red blood cells were lysed by 
adding 5 ml of ice cold Guy’s solution to the cell pellet. Cells were incubated on 
ice for 2-3 min then lysis was stopped by addition of 10 ml medium containing 
10% FCS. Additional debris were removed and cells were washed once with 
fresh medium. Isolated cells were either directly used for staining or were 
cultivated in base D-MEM medium with 10% FCS. 
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Preparation of mouse bone marrow derived dendritic cells 
Bone marrows were isolated from mouse femurs and tibias. After the 
removal of muscles both ends of bones were cut and marrows were flushed out 
with 2 ml of base culture medium using a syringe. Cells were resuspened by 
pipetting and then washed. In order to generate the DCs were cultivated for 8 
days in base cell culture medium supplied with 5% FCS and 1000 U/ml of mGM-
SCF. 
The DC differentiation was checked by surface staining evaluating expression of 
CD11c, CD1d and MHC class II. 
 
Activation assays with Tg T cells 
Human and mouse APC were incubated with 50 µg/ml of ZOL for 2 h at 
37°C then washed twice with PBS. APC (1-1.5 x 106/well) were incubated with 
freshly isolated mouse thymocytes or splenocytes (3 x 106/well) for 24 h in 24 
well plates and then samples were analyzed by surface staining. In some 
experiments anti-TCR mAbs were bound to the plastic at 5 µg/ml for 12 h at 4°C 
then wells were washed and thymocytes or splenocytes were added and 
incubated as before. As a positive control thymocytes were activated in the 
presence of 5 µg/ml of Concanavalin A (ConA, Calbiochem). 
 
Cell surface markers staining 
 Cells were washed with FACS-buffer (0.5% human albumin, 0.02% NaN3 in 
PBS) and incubated with the primary mAbs or with the appropriate isotype-matched 
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irrelevant mAb for background determination. After washing with FACS buffer cells 
were stained with fluorochrome conjugated secondary reagents. All incubations and 
washings were done at 4°C in FACS-buffer. 
 
Intracellular staining 
Cells were washed three times with PBS, fixed with 2% paraformaldehyde 
(PFA, Merk) solution in PBS for 15 min at room temperature and washed three 
times with FACS-buffer. In order to permabilized cell membrane, cells were 
incubated in 0.1% saponin (Sigma-Aldrich) FACS-buffer for 5 min at room 
temperature. Cells were stained with primary antibodies or isotype matching 
control antibodies, then washed three times and incubated with of fluorochrome 
conjugated secondary reagents. All incubation steps for staining were done at 
room temperature for 30 min and all the reagents were prepared in FACS-buffer 
containing 0.1% saponin. 
 
Flow cytometry 
The following antibodies specific for human determinants were used: anti-
HMGR (A9) from ATCC, anti-hTCR Vγ9 (B3) and anti-hTCR Vγ2 (4G6) 
antibodies as previously described (Carena et al., 1997). 
The following antibodies specific for mouse determinants were used: anti-CD3ε 
(145-2C11), anti-CD4 (GK1.5), anti-CD8α (53-6.7), anti-CD11c (HL-3) and anti-
CD24 (M1/69) from BD Biosciences; anti-CD5 (CG16), anti-CD69 (H1.2F3), anti-
CD62L (MEL-14) and anti-CD25 (PC61 5.3) from Caltag; anti-CCR7 (4B12), 
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(kindly provided by Professor Zwirner, University of Göttingen, Germany), (Ritter 
et al., 2004). Anti-CD1d (HB322) and anti-MHC class II (m5 114) purified from 
hybrydoma culture supernatants. 
BirA-tagged HMGR was followed with Bir1.4 mAb (Nowbakht et al., 2005). 
The following secondary reagents were used: Goat Anti-Mouse IgG Alexa 647 
(Molecular Probes), Goat Anti-Mouse IgG FITC (SBA), Goat Anti-Mouse IgG PE 
(SBA), Streptavidin RPE (SBA), Streptavidin APC and Streptavidin PE-TR 
(Caltag) were used as revealing secondary reagents when the mAbs were not 
directly labeled to fluorocromes. 
Samples were analyzed using CyAn ADP flow cytometer (DakoCytomation, 
Baar, Switzerland). Nonviable cells were excluded from the analysis using light 
scatter and incorporation of propidium iodide (Fluka). Data were analyzed using  
Summit 4.2 software (DakoCytomation). 
 
Chemotaxis assay 
Chemotaxis was assyed in 48-well Boyden microchambers (Neuro Probe, Cobin 
John, MD) by using polyvinylpryrrolidone-free polycarbonate (Nucleopore) 
membranes as previously described (Paoletti et al., 2005). In brief, thymocytes 
after selection were cultured for an 18 h before the chemotaxis assay. 1 x 105 
cells diluted in chemotaxis buffer (RPMI 1640, 20 mM HEPES, 1% BSA) were 
added to the upper wells (30 µl/well). The attractive chemokine SLC (R&D) 
diluted in chemotaxis buffer was placed in the lower well at different 
concentrations. After 60 min of incubation, the membrane was removed, washed 
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in the upper side with PBS, fixed (50% methanol) and stained (Diff-Quick, 
DADE). Migrated cells were counted at 1000-folds magnification in 5 randomly 
selected fields. All the experiments were performed in triplicate.  
 
Production of monoclonal antibodies from hybrydoma 
Hybridoma cells producing monoclonal antibodies (mAb) were cultured 
and expanded in medium containing 10% FCS and then adapted to 5% FCS 
medium. For final antibody production cells were cultivated in flasks (175 cm2, 
BD Falcon) in medium containing 3% low IgG serum (Gibco). mAb were purified 
from collected supernatants using 5 ml protein G column (HiTrap ProteinG, 
Pharmacia). The column was connected with a peristaltic pump (2132 
Mikroperpex peristaltic Pump, LKB Bromma) and equilibrated with PBS, before 
the hybridoma supernatant was loaded at a flow rate of approximately 1 ml/min 
at 4°C. Each time 500 to 1000 ml of supernatant wer e used for antibody 
purifcation. After supernatant loading, the column was connected with an UV-
spectrophotometer (2238 UVICORD SII, LKB Bromma) set at 280 nm and 
washed with PBS until all contaminating serum components were removed. Then 
the antibody was eluted with a solution of 100 mM glycine dissolved in water at 
pH 3.0. The antibody was collected in 15 ml tubes and immediately neutralized 
with 500 µl of a Tris solution (1M, pH 7.4). The antibody was filtered, NaN3 was 
added at a final concentration of 0.02% and the concentration was determined 
with an UV-spectrophotometer (V-530, Jasco) at 280 nm wavelength. An OD of 
1.3 was estimated to correspond to 1 mg/ml of antibody concentration. 
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Biotinylation of purified antibodies 
The purified antibody solution was dialyzed against borate buffer (pH 8.5) 
containing 0.2 M H3BO3 (Fluka), 0.1 M KCl (Fluka), in order to remove all small 
organic molecules containing free amino groups. Dialysis was performed in 
dialysis tubes (3.5 kDa cutoff, Spectra/Por CE Float A Lyzer, Spectrum). 
Antibody concentration was adjusted to at least 1 mg/ml. Biotinylation was 
performed in the borate buffer pH 8.5 in small glass vials containing a magnetic 
stirrer. During stirring at room temperature, biotin-NHS ester (Sigma-Aldrich) was 
added stepwise (in 4 steps) at 5 min interval between each addition step. The 
amount of biotin was calculated as 20 times molar excess to antibody molecules, 
so that ratio between biotin-NHS ester:antibody was 20:1. 
Biotin-NHS ester was dissolved in DMSO under nitrogen atmosphere at a 
concentration of 10 mg/ml. After the last addition of biotin-NHS ester, the solution 
was further stirred for 30 min then dialyzed against PBS. The concentration of 
the biotinylated antibody was determined by UV-absorption as described and 
success of biotinylation was tested by either FACS staining or by ELISA. 
 
Statistical analysis 
The Dunnett Multiple Comparison Test was used to compare groups in the semi-
quantitative RT-PCR experiments, HMGR phosphorylation studies and HMGR, 
MVK, PMVK and MVD activity assays. One-tailed P value was calculated for 
comparison of PP2A activity between experimental groups. 
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